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ABSTRACT
ASSESSMENT OF PHYSICAL ACTIVITY AND SEDENTARY BEHAVIOR
USING WEARABLE SENSORS: MEASUREMENT CONSIDERATIONS AND
CLINICAL APPLICATIONS
May 2017
AMANDA M. HICKEY, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Patty S. Freedson

The aims of study one of this dissertation were two-fold: 1) To understand
the variability of sedentary behavior (SB) throughout a seven-day measurement
period and 2) To determine the number of days of SB measurement required to
reliably estimate seven-days of measurement. To address these aims, we
utilized activPAL (AP) data from two existing data sets from the Physical Activity
(PA) and Health Laboratory. Data were from 62 adults and 34 adolescents who
had seven consecutive days of valid monitor wear. We found that adults were
more sedentary on weekdays compared to weekend days, but there were no
differences by type of day in adolescents. Results also suggest that two days of
wear in adults and three days of wear in adolescents provide estimates
comparable to a seven-day day measurement period. Our observation that less
than seven-days of data are needed to reliably estimate SB is a novel finding and
will reduce measurement burden for researchers and participants in future
studies.
For study two, we sought to determine the feasibility of assessing SB/PA
with wearable sensors in a clinical population. More specifically, the aims of this
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part of the dissertation were 1) To quantify changes in objectively measured PA
and SB using an AP during the natural progression of osteoarthritis (OA) over a
nine-month period and 2) To determine the relationship between change in
objectively measured PA and SB and patient reported pain and function.
Participants were monitored immediately following a baseline clinic visit and after
three, six, and nine-month follow-up visits. In addition, we correlated these
PA/SB metrics with patient-reported changes in pain and function. We found no
changes in any SB metrics (% of time spent sedentary, breaks per day, and
break-rate) at three, six, and nine months in comparison to baseline. There were,
however, significant declines in activity metrics (% of time spent stepping,
guideline minutes, guideline bouts, % of time spent in moderate-to-vigorous PA
and steps per day) at each subsequent time-point. The percent change for
declines in activity metrics ranged from 0.1% to 42%. The R2 values describing
the relationship between the SB/PA variables and the patient reported pain and
function using the WOMAC were all low (range: 0 to 0.14). The results from this
part of the dissertation demonstrate that it is a feasible approach to longitudinally
quantify natural changes in PA/SB as OA progresses and they also provide
insight into how activity behavior changes over time and informs the literature
that interventions to help individuals maintain their PA levels are warranted.
The aims of study three were: 1) To determine if the ActiGraph (AG) and
AP provide comparable estimates of PA and SB in a sample of patients with OA
and 2) To compare the relationships between patient-reported pain and function
and PA/SB measures from the AP and AG accelerometers. Two SB cutpoints
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from the AG were utilized (100 counts∙min-1 (AG100) and 150 counts∙min-1
(AG150)).
There were significant differences between the AP and AG150 for measures of
% of time spent sedentary (difference of 6.3%), breaks per day (difference of 30
breaks), and steps per day (difference of 879 steps). There were significant
differences between the AP and AG100 for breaks per day (difference of 30
breaks) and steps per day (difference 640 steps). Average guidelines minutes
and number of guidelines bouts were comparable among the AP, AG100 and
AG150. The association between the SB and PA variables and the patient
reported pain and function were very weak (all R2 values < 0.07) for the AP and
AG. This last study provides evidence that researchers should be cautious in
comparing PA/SB findings across studies that use different wearable sensors to
assess SB/PA behavior.
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CHAPTER I
INTRODUCTION
Statement of the Problem
The literature supports a consistent, inverse relationship between physical
(PA) and health outcomes such as cardiovascular disease, type 2 diabetes, and
obesity (1). More recently, evidence has accumulated suggesting that sedentary
behavior (SB) is associated with an increased risk of developing these
diseases (21, 34, 35). Much of the evidence for these health-behavior
relationships was established through large-scale epidemiological studies. These
epidemiological studies often rely on self-report tools to measure PA and SB, as
these tools are convenient and inexpensive. However, self-report tools are
susceptible to measurement error arising from recall bias and/or social
desirability (2, 92). Therefore, using self-report may lead to misclassification of
PA and SB levels and in turn may attenuate the relationship between these
behaviors and health outcomes (12). These limitations of self-report are a
problem as any PA and SB research (e.g., cross-sectional, experimental,
longitudinal) relies on accurate and precise measurement of habitual, free-living
behavior.
Objective measures (e.g., accelerometers) of PA and SB are more accurate
and precise than self-report tools (46, 56, 80). In the past, the inconvenience and
cost have prohibited their use in large-scale studies. However, accelerometers
have evolved over time (e.g., longer battery life, larger memory capacity, and
lower cost) and thus have become more feasible to use in large-scale
studies (95). There are large volumes of PA and SB data in healthy adults from
1

epidemiological studies such as the NHANES and BRFSS (22, 69, 94). These
data are useful and applicable for making judgments about the activity habits of
the general population, but may not pertain to specific clinical populations.
However, measuring PA and SB in clinical populations such as those with
osteoarthritis (OA) may be of particular importance. Clinical populations where
mobility is affected may be more susceptible than the general population to
adopting a sedentary lifestyle and may be at higher risk for developing comorbidities known to be related with a sedentary lifestyle. In addition, there may
be certain chronic diseases that may alter or be affected by SB or PA. Possible
reasons these behaviors may be important to measure in clinical populations
include: 1) To determine if these populations meet the national PA guidelines, 2)
To determine if changes in PA/SB occur while the disease progresses, and 3) To
determine if changes in PA and SB occur after different treatments. All of these
reasons rely on the accurate and precise measurement of these behaviors.
Therefore, objective evaluation of PA and SB in clinical populations is warranted.
However, with an increase in the utilization of these types of devices, it is
important to insure that results from studies that use different accelerometers are
comparable. This dissertation addressed three knowledge gaps in assessing
PA/SB using wearable sensors. The first study addressed a fundamental
methodological issue in reliably estimating habitual PA and SB. The second
study utilized accelerometers to measure PA and SB in a longitudinal manner in
patients with OA. The third study compared PA/SB output from two different
accelerometers (the activPAL (AP) and ActiGraph (AG)) and the relationships
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between patient-reported pain and function and PA/SB measures from the AP
and AG accelerometers.
Aims of Dissertation Studies
Study One: How Many Days Are Needed to Reliably Estimate Habitual
Sedentary Behavior?
It is important to capture habitual patterns of behavior in studies examining
health-behavior relationships (e.g., the relationship between diabetes risk and
PA). Habitual patterns of PA/SB may be difficult to ascertain using
accelerometers, as it is not feasible for a study to monitor participants for weeks
or months at a time. Therefore, a fundamental methodological issue in activity
monitoring is to insure that the activity monitoring period reliably captures
habitual behavior. To understand this issue, the variability of both PA and SB
must be considered. Patterns and variability of PA behavior in both adults and
adolescents has been well studied in the literature (25, 26, 51, 94). Previous
research has demonstrated that in adults at least three to five days of monitor
wear are necessary to reliably estimate PA (ICC=0.80) (52, 68, 96). Therefore, a
common protocol used in large-scale epidemiological studies, such as NHANES,
is to have participants wear an accelerometer for a seven-day period and to
include data in subsequent analyses for participants who provide at least three to
five days of data. Despite the abundance of literature regarding the variability in
accelerometer measured PA behavior, much less is known about variability
characteristics in accelerometer measured SB. For example, there are limited
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data regarding whether there are day-to-day and weekend day versus weekday
differences in SB.
The few studies that do examine whether there are day-to-day differences
in SB have equivocal findings where some studies demonstrate day-to-day
differences (16, 41, 66) while others do not (56, 100). In addition, there are also
conflicting findings on whether there is an effect of day status (weekend day vs.
weekday) on SB (56, 88, 100). Based on the conflicting findings, further work is
required to understand the variability of accelerometer measured SB.
There is also a paucity of data regarding the number of days necessary to
reliably estimate SB. Studies that have examined this have found a range of
three to seven days are needed (16, 41, 68). However, the studies that have
been conducted contain drawbacks such as limitations in the type of device that
is used to measure SB and the metric used to estimate SB. Further investigation
into day-to-day differences and the number of days needed to estimate SB
should: 1) include the use of the AP accelerometer, which is an accurate and
precise measure of SB compared to direct observation (55), 2) use a metric of
SB that takes into account wear time, and 3) be conducted in both adults and
adolescents.
The aforementioned studies were all conducted in adults. In adolescents,
patterns of SB on weekend and weekdays have been mostly identified using selfreported time spent viewing television. The few studies that use an
accelerometer to measure SB demonstrate mixed results on whether there is an
effect of day status on SB (38, 51) and find that three days are needed to reliably
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estimate SB in adolescents (6). Understanding the patterns of SB in adolescents
in important as the literature consistently demonstrates a decline in PA during
adolescence (18). Therefore, this first dissertation study addressed the limitations
in the current literature by combining AP data from two previously conducted
studies in the Physical Activity and Health Lab that includes both adults and
adolescents. The AP data collection and processing methods were identical in
the two studies. The combined data were used to examine day-to-day
differences in SB and determine the number of days needed to reliably estimate
habitual SB.
1. Specific Aim: To determine if there are day-to-day differences in SB.
a. Hypothesis: There will be no day-to-day differences in SB.
2. Specific Aim: To determine the number of days required to reliably
estimate habitual SB.
a. Hypothesis: The number of days required to estimate habitual SB will
be the same as number of days required to estimate habitual PA.
Study Two: A Longitudinal Assessment of Accelerometer Measured
Physical Activity and Sedentary Behavior in Adults with Osteoarthritis
OA is a disease in which there is no consensus in the literature regarding
a single symptom or test to diagnosis or monitor progression of the disease (3). A
current method used to assess symptoms and/or progression of the disease is by
monitoring a patient’s functional ability, or the ability to carry on normal daily
activities. A patient’s functional ability is assessed via self-reported
questionnaires such as the WOMAC or by objective functional performance

5

measures such as the chair stand test (65). While self-report provides
information on perceived ability and the objective functional performance
measures provide some information on actual ability, they do not necessarily
reflect a patient’s functional status in everyday living (76). Therefore, they do not
provide physicians with information on the impact of OA on daily function or
treatment effectiveness.
Wearable devices such as accelerometers have the capability of
measuring free-living behavior and metrics from these devices may provide
physicians and other health care professionals more information that
comprehensively characterizes individual function and how OA patients are
affected in their daily life by symptoms of OA. There are data that support this
notion. Accelerometer-measured PA is reportedly related to improved physical
function (13) and a higher amount of accelerometer-measured sedentary time
has been shown to be related to reduced physical function (59). While these
relationships may be important to physicians and other health care professions,
before these devices are implemented in a clinical setting, it is necessary to
collect objectively measured PA and SB in OA patients as the disease
progresses. Accelerometer data collected longitudinally can be used to quantify
natural changes in these PA/SB metrics as the disease progresses, which will
help to develop appropriate PA and SB guidelines in this population. In addition,
examining the relationship between these PA/SB metrics and pain and function
will help to inform the development of future interventions designed to maintain
physical function in these patients.
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Another methodological consideration is the type of accelerometer that is
utilized. Since SB has been identified as an important health-related behavior,
employing a wearable sensor that accurately measures this behavior is important.
The majority of accelerometer-measured PA and SB data in a population with OA
come from the Osteoarthritis Initiative (OAI). The OAI includes those who already
have knee OA or at risk of developing it and uses the AG hip-worn accelerometer
to measure PA and SB. This device lacks sensitivity for measuring changes in
SB (55). In contrast, the AP is an accurate and precise measure of SB and is
sensitive enough to detect changes in SB (55). To our knowledge, few published
studies exist that use the AP in patients with OA (63, 93). Therefore, the primary
aim of this study was to determine if there are changes in PA and SB assessed
with the AP accelerometer during the natural progression of knee OA over a
nine-month period. The second aim was to determine if AP accelerometer
measures of PA and SB are related to patient reported pain and function at each
time-point. Fifty patients from the Arthritis and Total Joint Center on the UMass
medical campus were recruited. Participants wore an AP accelerometer to
measure PA and SB levels for 7-days at baseline, 3-months, 6-months and 9months. Patients also self-reported their pain and function levels at each of the
time points.
3. Specific Aim: Determine if there are changes in PA and SB using the AP
accelerometer during the natural progression of knee OA over a 9-month
period
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a. Hypothesis: SB will increase and PA will decrease during the natural
progression of knee OA over a 9-month period
4. Specific Aim: Determine if AP accelerometer measures of PA and SB are
related to patient reported pain and function at each time-point (baseline,
3-month, 6-month and 9-month
a. Hypothesis: Accelerometer measures of PA and SB will be related to
patient reported pain and function at each time-point (baseline, 3month, 6-month and 9-month
Study Three: Comparison of Output From Two Accelerometers in a
Population With Osteoarthritis
There is substantial information regarding activity level in healthy adults
from epidemiological studies such as the NHANES and BRFSS (22, 69, 94).
However, measuring PA and SB in clinical populations with mobility limitations
may be particularly important, as they may be more likely than the general
population to adopt a sedentary lifestyle. Individuals with OA is a clinical
population that may be at higher risk for developing co-morbidities that are
associated with a sedentary lifestyle (21). However, the majority of studies
examining activity behavior in OA patients have relied on self-report, which has
limited reliability and validity compared to more objective measures of activity
(e.g., accelerometers) (80). Fortunately, accelerometers have become more
ubiquitous (95) and are being used to measure activity behavior in individuals
with OA (19, 27).
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While the use of accelerometers in patients with OA has increased over
time, a current concern is whether results from studies that use different
accelerometers are comparable. In recent years, the AP has been more widely
used for the measurement of SB as it is has been shown to be more accurate
and precise than the AG for estimating SB in the free-living environment (53).
The AP’s accuracy, precision, and ability to measure time spent in different
postures (sitting/lying, standing/stepping) as well as time spent in different
intensities (sedentary, light and MVPA) make this device attractive to
researchers (32, 84). The OAI provides the majority of PA and SB data in
patients with OA and the AG is utilized to measure these behaviors. Therefore, it
is important to determine if differences between AP and AG estimates of PA/SB
exist. If differences in outcome measures exist between monitors, this will have
implications for comparing activity and SB measures across studies that use
different monitors. In addition, differences in monitor output may impact the
relationships between activity behavior and symptoms of OA (e.g., pain and
physical function). Therefore, the primary aim of this study was to determine if
the AG and AP provide comparable estimates PA and SB in a sample of patients
with OA. The secondary aim of this study was to compare the relationships
between patient-reported pain and function and PA/SB measures from the AP
and AG accelerometers. We used baseline measures from the longitudinal study
in OA (study two) patients to determine if the AG and AP provide comparable
estimates PA and SB in a sample of patients with OA and to compare the
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relationships between patient-reported pain and function and PA/SB measures
from the AP and AG accelerometers.
5. Specific Aim: To determine if there are differences in monitor-based
estimates of PA and SB between AP and AG accelerometers in
individuals with OA.
a. Hypothesis: There will be differences in monitor-based estimates of PA
and SB between the AP and AG accelerometers in individuals with OA.
6. Specific Aim: To compare the relationship between objectively measured
free-living PA and SB and patient reported function using both the AP and
AG tools for estimating PA and SB in persons with OA
a. Hypothesis: The relationships between objectively measured free-living
PA and SB and patient reported function will be different when using
the AP and AG in persons with OA
Significance of Dissertation Studies
The results of the first study answer a fundamental methodological issue
in the SB measurement field by providing information on the monitoring period
necessary to reliably capture habitual SB. This adds to the paucity of data in this
area in the measurement field and builds upon the limitations of the few studies
that have been conducted in this area by: 1) Focusing on a more diverse
participant sample (e.g., broad ages, BMIs, and activity levels), 2) Utilizing an
accurate and precise measure of SB that is commonly used in studies to
measure SB, and 3) Accounting for wear time presenting metrics as percent of
wear time. It is typical for studies to use one week of monitor wear as their study
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protocol and if participants have provide at least four valid wear days (10 hours of
wear or more) the data are used in subsequent analyses. However, being able to
use less than four days of data to estimate habitual SB could reduce participant
burden and allow researchers to include more data in their analyses.
The results of the second study add new information to the limited number
of studies on objective measures of PA and SB in patients with OA. More
research groups are recognizing the importance of establishing measures of
these behaviors in clinical populations. The longitudinal study design uses
improved objective measures of SB and PA and determined how these behaviors
change as the disease naturally progresses. Findings from this study will be
useful in a clinical setting to: 1) develop appropriate PA and SB guidelines in this
population as it provides information on the currently activity and sedentary levels
of this type of population and 2) Determine targets for interventions to maintain
physical function in this population.
The results of the third study have significant implications in the field
regarding objectively measured PA and SB in adults with OA. It helps to
determine if activity and SB levels can be compared across studies that use
different monitors. It also will determine if the PA/SB metrics from different
monitors have similar relationships with patient reported pain and function. If the
relationships differ depending on what type of monitor is used that could also
have implications on cross-study comparisons.
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CHAPTER II
REVIEW OF THE LITERATURE
This review of the literature will describe the main areas of research that
will be addressed in this dissertation. First, the literature pertinent to study one
will be addressed. The current knowledge on reliably estimating habitual physical
activity (PA) will be presented along with the limited information regarding reliably
estimating habitual sedentary behavior (SB). Second, the literature needed to
explain the importance of measuring PA and SB in a population with
osteoarthritis (OA) is discussed. This literature is applicable for both study two
and three, which investigate different questions within a population with OA.
Reliably Estimating Habitual PA Levels Using Accelerometers
For studies that examine PA and SB levels of populations and/or healthbehavior relationships, it is important to take into account that there may be
variability in these behaviors. This variability should be considered during study
design and analysis to reliably reflect habitual patterns of behavior. lf these
behaviors are being measured using a wearable device, the variability of these
behaviors will also have an effect on the number of days that participants should
wear the device and this in turn will have an effect on the monitor wear protocol.
The number of days that participants wear the device will affect sample size and
also the ability to capture differences in activity levels and/or establish healthbehavior relationships (7). Therefore, determining the minimum number of days
needed to reliably estimate habitual PA and SB is a fundamental methodical
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issue in activity monitoring because it is not logistically feasible to have
participants wear activity monitors for weeks or months at a time.
The body of research examining the number of days needed to reliably
estimate habitual behavior using accelerometers has focused primarily on the
measurement of PA. Before the number of days needed to reliably estimate a
behavior is established, day-to-day variability in this behavior must be
understood. Patterns and variability of PA behavior in both adults and
adolescents has been well studied in the literature (25, 26, 51, 94). Matthews et
al. examined sources of variance in accelerometer-based (Computer Science
Applications) measures of PA in healthy adults (average age= 45 years) (68).
They found that day status (e.g., weekend vs. weekday) accounted for a small
proportion (1-8%) of the variance in PA. The participants performed more
moderate-to-vigorous activity on Saturdays than Sundays, but this was not
significant. However, women performed significantly more moderate-to-vigorous
activity on Saturdays compared to weekdays. There were no significant
differences in moderate-to-vigorous activity across weekdays. Intra-individual
variation was found to contribute 30-45% to the overall variance of PA where as
the majority of the variance (55-65%) was accounted for by inter-individual
variation. Taking into consideration these sources of variance, Matthews et al.
determined that at least three to four days of monitoring were necessary to
achieve 80% reliability in estimates of time spent in moderate-to-vigorous activity
or total activity counts in adults (68). Similarly, Hart et al. reported three days of
accelerometer data (ActiGraph (AG) 7164) were needed to achieve 80%
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reliability in estimates of total PA levels in older adults (average age = 69 years)
and that only two days were needed to estimate moderate-to-vigorous PA (41).
This number of days is lower than findings that seven to ten days are required to
reliably estimate PA behavior from self-report tools such as questionnaires or PA
logs (70). Based on studies such as those mentioned previously and others using
accelerometers (14, 33) and pedometers (97), the general consensus in the
literature is that at least three to five days of monitor wear are necessary to
achieve reliable estimates of PA in adults. Therefore, a common protocol used in
large-scale epidemiological studies, such as NHANES, is to have participants
wear an accelerometer for a seven-day period. This protocol is used to reduce
individual variability (68) and account for potential differences that may occur to
day status (e.g., weekday vs. weekend day).
Reliably Estimating Habitual SB Levels Using Accelerometers
Over time, evidence has accumulated suggesting that SB is negatively
related to health outcomes (21, 34, 35). Consequently, there has been increased
interest in the measurement of SB in various populations for surveillance
purposes and for exploring the relationship being SB and health outcomes. A
popular and convenient method to measure SB has been via self-report, but this
methodology has been shown to have high variability and limited agreement with
criterion measures (43). A more accurate and precise method of measuring SB is
through the use of accelerometers (46, 56, 80), which have become more
feasible to use in large scale studies (95). However, despite the large body of
evidence regarding the variability in accelerometer measured PA behavior, there

14

is much less known about variability characteristics in accelerometer measured
SB and little known about the number of days necessary to reliably estimate this
behavior.
In studying the variability of SB, researchers have sought to determine if
there are day-to-day differences in SB. Three studies using an AG accelerometer
in older adults found no day-to-day differences in SB and that there were no
differences between weekday and weekend day SB (16, 41, 66). Similarly, using
the activPAL(AP), Smith et al. reported no differences between sitting time on
weekdays and weekend days in a population of office workers (88). In contrast,
Visser & Koster and Kozey-Keadle et al. reported differences in SB between
weekday and weekend days (56, 100). However, their findings were also
conflicting. Using an AG accelerometer, Visser & Koster found SB was higher
during the weekend compared to the weekdays (100) whereas using an AP
accelerometer Kozey-Keadle et al. reported that participants were more
sedentary on weekdays compared to weekend days (56).
In adolescents, self-reported time spent viewing television is commonly
used to establish patterns of SB. There are few studies that exist using
accelerometer measured SB and they demonstrate mixed results. For example,
Harrington et al. showed no effect of day status on SB using the AP in
adolescent females 15-18 years old (38). In contrast, Jago et al. reported week
and weekend day differences in SB in eighth graders using the Manufacturing
Technologies Inc. accelerometer (51). Based on the conflicting findings, further
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work is required to characterize and understand the variability of accelerometer
measured SB in both adults and adolescents.
Despite the number of studies examining the prevalence of SB and its
relationship with health, there are limited data in the literature regarding the
number of days that are needed to reliably estimate SB. It is reasonable to
suggest the number of days to reliably estimate SB may be different than that for
PA behavior. These are two distinct behaviors each of which have independent
relationships with health (31, 45). However, few studies have addressed this
important knowledge gap. Matthews et al. found that seven days of monitoring
using the Computer Science Applications (CSA) accelerometer were required to
reliably estimate inactivity (68). However, inactivity was defined as 0-499 activity
counts per minute. This count cut-point encompasses both light activity and SB.
Hart et al. examined the number of days needed to reliably estimate SB using the
AG 7164. They found no statistical differences between time spent in SB among
any of the days of the week (range: 412 minutes to 437.1 minutes). They also
found that any five days of the week reliably predicted total time spent in SB (i.e.,
do not need to capture a weekend day). The data in this study was only collected
in older adults and therefore, results may be limited to an older population. There
are two limitations of both studies. The first is that the outcome variable was
presented in absolute time spent in SB, which does not account for different wear
times. The second is that both studies use accelerometers that contain
acceleration sensing technology (piezoelectric sensor) that was replaced in
updated models of the AG in the mid 2000s. A recent study by Basterfield et al.
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in children aged 6–8 years does account for wear time in their SB metric (6).
They reported that three days of monitoring provided a reliability coefficient of
0.73 for estimates of percent time spent sedentary using an AG GT1M (6).
Similarly, a recent study by Donaldson et al. uses current models of the AG that
contain upgraded acceleration sensing technology in adults 19-90 years of age
and accounts for wear time in the SB outcome variable. They reported that any
four days of SB measurement provided estimates of SB comparable to a 7-day
wear period (16).
Based on the limited knowledge and conflicting findings on variability in
SB and also the number of days needed to reliably estimate SB in existing
studies, further work is needed. This further investigation should: a) include the
use of the AP accelerometer, which is an accurate and precise measure of SB
compared to direct observation (55) b) Account for wear by presenting SB as
percent of wear time, and c) be conducted in both adults and adolescents. In
conclusion, while the aforementioned studies were worthwhile first steps, more
research establishing day-to-day variability in SB and ultimately the number of
days needed to accurately represent habitual SB is warranted.
Burden of Osteoarthritis
Osteoarthritis (OA), a degenerative joint disease caused by the
breakdown of cartilage in one or more joints, affects approximately 27 million
American adults (58). The prevalence of OA is anticipated to increase drastically
due to increases in obesity rates and our aging population (48). The increased
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prevalence is of concern as this is a costly chronic condition that can lead to
functional impairment and decreased quality of life (17, 57, 102).
Current Methods of Tracking Progression of OA
In other chronic diseases, there are established methods to diagnose and
determine how the disease is progressing over time. For example, bone mineral
testing is important for diagnosing and monitoring a patient’s progress and
response to different osteoporosis treatments. In contrast, there is no consensus
in the literature regarding a single symptom or test to diagnosis or monitor
progression of OA (3).
Currently, the diagnosis of OA is based on a variety of measurements
such as clinical symptoms (e.g., pain with weight bearing activity and stiffness in
joints) along with some type of imaging criteria (e.g., radiographic evidence of the
joint space width) (9). One problem with these diagnostic criteria is that over the
years researchers have cited many limitations of radiography (e.g., technical
issues, sensitivity/specificity issues) (49). One major issue with using radiography
is that OA is a degenerative disease and there are patients who present with OA
symptoms who has no radiograph evidence of OA. In contrast, a patient may
have no symptoms, but show radiograph evidence of OA. These problems are
highlighted in an analysis of NHANES data conducted by Hannan et al (36). They
found that in 1762 individuals who had a physician diagnosis of OA, only 11%
had evidence of radiographic knee OA and only 34% of them reported clinical
symptoms such as knee pain. Therefore, there was a high level of discordance
between radiographic evidence of OA of the knee, knee pain, and a physician’s
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diagnosis. Because of such limitations, researchers have examined biochemical
markers in the blood, urine or synovial fluid samples that reflect changes in the
joint remodeling process and thus, provide some biologically-based measure that
quantifies disease progression (83). However, the European Society for Clinical
and Economic Aspects of Osteoporosis and OA stated there is no single
biochemical marker that is validated to become the gold standard for diagnosis
and tracking progression of OA (62). In addition, biochemical
markers/radiographic evidence may not make a difference to a patient..
Therefore, there is clearly still a need for a method for diagnosing and tracking
progression of OA using an approach that is more patient-centered.
Currently, one patient-centered approach is to monitor progression of the
disease is by monitoring a patient’s functional ability, or the ability to carry on
normal daily activities. Physicians can assess a patient’s perceived functional
ability via self-report questionnaires (e.g., WOMAC) or try to establish actual
functional ability via objective measures (e.g., timed 20-meter walk) (65).
However, both of these types of measures do not necessarily reflect a patient’s
functional status in everyday living (76). Therefore, they may not provide
physicians information on the impact of OA on daily function or treatment
effectiveness. An alternative to these commonly used methods may be to
measure free-living PA and SB using accelerometers. This may provide
physicians and other health care professionals more information that
comprehensively characterizes individual function and how OA patients are
affected in their daily life by symptoms of OA.
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The remainder of this literature review provides information on how these
devices have been used in past research in OA patients, a potential
measurement issue that may arise with the increased utilization of these devices,
and the relationship between PA/SB metrics and functional outcomes in patients
with OA.
Accelerometer-Based Measures of PA and SB in Patients with OA
OA commonly results in chronic pain and stiffness. These symptoms,
particular during ambulation, may create a barrier to being active in individuals
with OA. Therefore, measuring PA and SB in a population of OA with mobility
limitations due to chronic pain and stiffness may be particularly important, as they
may be more likely to adopt a sedentary lifestyle. It is common to measure
activity behavior in OA patients with self-report tools. However, self-reporting of
activity behavior is a method shown to be unreliable and not valid compared to
more objective methods (e.g., accelerometers) (80). However, due to
technological advancements, accelerometers have become more ubiquitous (95)
and are being used to measure activity behavior in individuals with OA (19, 27).
Despite the known benefits of PA for individuals with OA (24, 78, 79), both
data from self-report and accelerometers suggest that individuals with OA are not
sufficiently active. While they both suggest a low percentage of adults with OA
meet PA guidelines, there is a discrepancy between self-report and objective
measures. Self-report data from the BRFSS and NHIS studies suggest that
approximately 38% of adults with OA reportedly meet PA guidelines (28, 86)
where as these percentages are lower (13-30% meet guidelines) when using AG
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accelerometers in the OA Initiative (OAI) (19) and the Multidimensional
Intervention for Early OA of the Knee Study (27). Some of the only objective data
on SB levels in this population were obtained in the OAI. Adults in the OAI spent
approximately 10 hours in SB (19). This sedentary time is 12% higher than
similarly aged individuals in the NHANES cohort (69). SB may be a particularly
important measure to examine more thoroughly in this population due to the
accumulation of evidence suggesting that SB is associated with an increased risk
of developing negative health outcomes such as cardiovascular disease and
diabetes (21). This may be of particular importance in a population with OA as
they are at higher risk of developing co-morbid conditions such as cardiovascular
disease (87).
More studies need to utilize objective measures of PA and SB. One
important reason is that as stated above, there are discrepancies between selfreport and accelerometer findings. This may be due to limitations of self-report
tools, which includes that they tend to overestimate activity levels particularly in
older, obese populations (50) and also underestimate sitting time (98). The overreporting of activity and under-reporting of sedentary time may affect the
relationship found between these behaviors and health outcomes. Another
important reason to use wearable devices is that accurate and precise measures
of activity dose are important for developing PA/SB prescriptions. Due to
misclassification errors, self-report tools will not be able to accurately and
precisely provide this type of information. Accelerometers, however, can be worn
for seven-day periods and provide more accurate and precise information of
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habitual PA and SB. These data can be used to describe activity and SB using
different metrics (e.g., breaks from sitting time, minutes of bouts of activities that
last for at least 10 minutes or more).
Given the increased interest in SB as an independent risk factor for health,
the AP has been more widely used for measurement purposes as it is has been
shown to be more accurate and precise than the AG for estimating SB in the
free-living environment (53). The AP’s accuracy, precision, and ability to measure
time spent in different postures (sitting/lying, standing/stepping) as well as time
spent in different intensities (sedentary, light and MVPA) make this device
attractive to researchers (32, 84). The AP may be a more appropriate tool than
the AG (used in the OAI study) because SB may be a particular important
outcome in this clinical population. Only two studies in the literature have utilized
this device in patients with OA (63, 93). Lutzner et al. examined PA/SB metrics
using the AP before and one year after total knee arthroplasty (TKA) (63). They
found no changes in SB, however, they present this variable as hours spent lying
or hours spent sitting and standing. Presenting SB as hours spent lying only
ignores sitting behavior and including both sitting and standing hours together
combines both sedentary and light intensity activity (standing). Tonelli et al. used
the AP to examine differences in PA between men and women with knee OA
immediate prior to receiving a TKA (93). They found no differences in PA
between men and women. However, they do not present any SB variables from
this device.
While the use of accelerometers in patients with OA is certainly an
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advancement in the field and the need to utilize the AP to measure SB is
apparent, a current concern is whether results from studies that use different
accelerometers (in particular the AG and AP) are comparable. Differences
between estimates of PA/SB from different monitors do exist and this will have
implications for comparing activity and SB measures across studies that use
different monitors. In addition, differences in monitor output may impact the
relationships between activity behavior and symptoms of OA (e.g., pain and
physical function). An example of how differences in estimates of PA and SB can
impact relationships with health is demonstrated when using self-report and
accelerometer measured PA and SB. Using self-report to quantify PA and SB
reveals weaker relationships with metabolic and vascular disease risk factors
than when PA and SB are measured using an AG accelerometer (12). The selfreport tool leads to an underestimate of the strength of relationships with the risk
factors (12).
Previous work from our lab has shown that that the AP is more accurate
and precise than the AG in estimating SB compared to direct observation (55),
suggesting that interpreted output from these two devices is different. In addition,
studies that have examined the convergent validity between the AG and AP have
consistently demonstrated discordance between the two monitors for estimating
SB in both healthy children (67, 91) and adults (40, 43). It is not known if similar
discrepancies between the AP and AG will be observed in a sample of OA
patients. Therefore, comparing PA/SB output between the AG and AP and
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determining how metrics from each device relate to pain and function in a sample
of patients with OA is warranted.
PA, SB and Functional Outcomes in Patients with OA
In various randomized controlled trials PA programs have been shown to
provide substantial benefits to individuals with OA including improved
function (24, 78, 79). Some accelerometer evidence of this relationship between
PA and improved function was established using data from the previously
mentioned OAI study (20). The OAI is a cohort of around 5000 men and women
aged 45-79 years old that are at risk or currently have knee OA. Participants in
this study are followed for four-years and data are collected on imaging
biomarkers, biochemical and genetic markers, clinical assessments of pain and
function, and other risk factors including PA and SB. Each year PA and SB are
measured using the PA Scale for the Elderly (PASE) self-report questionnaire.
Functional performance is also evaluated each year using a timed 20-meter walk
test. Using these data, Dunlop et al. examined whether there is a graded
relationship between self-reported PA and future functional performance in
individuals with knee OA (20). They found that higher levels of PA were
significantly associated with better functional performance (e.g., higher gait
speed). Their data also showed that even individuals in physical activity quartile
2 (low activity) had better function than those quartile 1, the lowest activity level.
These data support the PA guidelines that suggest that some activity is better
than none. While this study was a worthwhile starting point, the PASE
questionnaire has been shown to have low agreement and inadequate validity
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when compared to an accelerometer in a group of men and women who have
undergone total knee arthroplasty (10). Therefore, the use of accelerometry may
be better suited to a population that would include individuals who have
undergone total knee arthroplasty.
The OAI also includes a cross-sectional accelerometer study (using the
AG GT1M) that was conducted in a sub-cohort at the four-year follow-up
examination. From this sub-study, Lee et al. report that more sedentary time was
related to reduced physical function and this was independent of time spent in
moderate-to-vigorous PA (59). Interestingly, 72% of the participants in the
highest SB quartile did not meet the threshold of a 4 feet/second walking speed.
This is alarming as this speed corresponds to the minimum walking speed
required to safely cross a street. The data in this study is cross-sectional and
therefore, raises the possibility of reverse causality. Also alarming, Song et al.
examined the relationship between SB at this 48-month follow-up and 2-year
onset of physical frailty (90). They found that greater baseline SB was strongly
related to incident of physical frailty and that this was independent of their
moderate-intensity activity level. Thus, SB may be a distinct risk factor for
physical frailty in this population. While this relationship was examined
prospectively, the baseline SB was still only collected after participants have
been enrolled in the OAI for 48-months. Therefore, while the data from the OAI
sub-study certainly sets the scientific framework for objective measurement of SB
and PA in individuals with OA, there are still important knowledge gaps that exist.
First, there is still no objective data on how PA and SB change as the disease
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progresses from diagnosis. Second, there are also limitations to the monitor itself
in terms of SB measurement. The AG is not the most appropriate accelerometer
for measuring SB, or changes in SB. Our lab has previously demonstrated the
AP is an accurate and precise measure of SB and is sensitive enough to detect
changes in SB as compared to direct observation (55). Third, it would be
important to measure different PA and SB metrics relate to physical function.
Metrics such as sedentary breaks (e.g., sit-to-stand or sit-walk transitions) and
minutes spent in PA bouts that last 10 minutes or more should be examined.
Measuring PA and SB before and after different treatment modalities (e.g.,
physical therapy, total knee replacements) can provide insight into the efficacy of
these various treatment options. The limited research in this area has focused on
using accelerometers to quantify changes in PA following surgical interventions
(e.g., total hip arthroplasty or total knee arthroplasty). There is an abundance of
evidence that demonstrates these surgeries effectively improve function and
decrease pain in patients (23), but there is limited evidence that these
improvements translate to more PA. The limited studies measure PA with
accelerometers at approximately six months post-surgery and the findings are
equivocal (11, 15, 37, 101). Brandes et al. and Walker et al. demonstrated
increases in PA at 6-months post-surgery (11, 101). In contrast, Harding et al.
and de Groot et al. found no significant changes in activity levels 6-months postsurgery (15, 37). The inconsistent findings may be due to differences in
measurement periods and PA metrics. Two of the studies only monitored
participants for one to two days (15, 101). Typically, in the PA assessment field
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at least four valid wear days are necessary to reliably estimate habitual activity
levels. Therefore, only one to two days of activity data may not necessarily
represent their habitual post-surgery activity levels. The other two studies
measured habitual activity level by monitoring their participants for one week (11,
37). The studies also all used different monitors including the StepWatch (11),
Numact Activity Montior (101), AG (37), and the Activity Monitor (15). These
different monitors also provide various PA metrics including gait cycles (11), total
ambulatory energy expenditure (101), average activity counts per minute (37),
and percent of time spent in movement-related activities (15). Most studies have
only focused on PA changes after surgical intervention. However, the changes in
PA levels after other non-surgical treatments also needs to examined to provide
insight into the efficacy of more conservative treatment options (e.g., physical
therapy). These types of treatments are common first steps before surgical
intervention is necessary. These studies should also include information about
SB, but only one study provides this information and they found no changes postsurgery (37). SB should be examined in more depth, as this population is
particularly susceptible to adopting a sedentary lifestyle. It is also possible that
examining these behaviors as the disease progresses could provide information
regarding if or when a participant will need surgery.
In conclusion, based on the current literature, it appears that before
accelerometer technology is implemented as a routine clinical measure, it is
necessary to collect objectively measured PA and SB in OA patients as the
disease progresses. Accelerometer data collected longitudinally can be used to
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quantity natural changes in these PA/SB metrics as the disease progresses,
which will help to develop appropriate PA and SB guidelines in this population.
Examining the relationship between these PA/SB metrics and pain and function
will inform the development of future interventions designed to maintain physical
function in these patients. It is possible that changes in SB may be a more
feasible goal and better suited for the OA population than changes in PA. Lastly,
the ability of the AP to accurately and precisely measure SB along with its ability
to detect changes in this behavior makes it appealing to use in a longitudinal
study.
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CHAPTER III
STUDY ONE - HOW MANY DAYS ARE NEEDED TO RELIABLY ESTIMATE
HABITUAL SEDENTARY BEHAVIOR?
Introduction:
The literature supports a consistent, inverse relationship between physical
activity (PA) and various health outcomes such as cardiovascular disease, type 2
diabetes, and obesity (1). Over the past decade, evidence has accumulated
suggesting that sedentary behavior (SB) is associated with an increased risk of
developing these aforementioned diseases (21, 34, 35). Consequently, there
has been increased interest in the measurement of SB in various populations for
surveillance purposes and for exploring the relationship to health outcomes.
In studies seeking to determine these health-behavior relationships (e.g.,
the relationship between diabetes risk and SB) it is important to capture habitual
patterns of behavior. In the past, a common method to estimate PA and SB has
been via self-report, but this methodology is susceptible to measurement error
arising from recall bias and/or social desirability (2, 92). Generally, objective
measures (e.g., accelerometers) of PA and SB are more accurate and precise
than self-report tools (46, 56, 80). In the past, the inconvenience and cost have
prohibited the use of accelerometers in large-scale studies. However,
accelerometers have evolved over time (e.g., longer battery life, larger memory
capacity, and lower cost) and thus have become more feasible to use in large
scale studies (95).
While these technological advancements in accelerometers have made
monitoring easier, habitual patterns of PA/SB may still be difficult to ascertain, as
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it may not be feasible for a study to monitor participants for weeks or months at a
time. Therefore, a fundamental methodological issue in activity monitoring is to
insure that the activity monitoring period reliably captures habitual behavior. To
understand this issue, the variability of both PA and SB must be considered. The
variability of these behaviors will also have an effect on the number of days that
participants should wear the device and this in turn has important implications for
sample size, monitor wear protocol and also effect size to insure that the
measurement is sensitive enough to capture differences in PA and SB
consequent to interventions and/or in establishing health-behavior
relationships (7).
Patterns and variability of PA behavior in both adults and adolescents has
been well studied in the literature (25, 26, 51, 94). It is generally accepted that in
adults and adolescents three to five days of monitor wear are necessary to
achieve acceptable reliability in estimating PA behavior (52, 68, 96). Therefore, a
common protocol used in large-scale epidemiological studies, such as NHANES,
is to have participants wear an accelerometer for a seven-day period and to
include data in subsequent analyses for participants who provide at least three to
five days of data. Despite the vast knowledge regarding the variability in
accelerometer measured PA behavior, there is much less known about variability
characteristics in accelerometer measured SB.
Three studies using AG accelerometers in older adults found no day-today differences in SB and that weekday and weekend day SB were not
significantly different (16, 41, 66). Similarly, using the AP, Smith et al. found no
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differences in total sitting time between weekdays and weekend days in a
population of office workers (88). In contrast, Visser & Koster (100) and KozeyKeadle et al. (56) reported differences in SB between weekday and weekend
days. Using an AG accelerometer, Visser & Koster found SB was higher during
the weekend compared to the weekdays (100) in a sample of older adults (65-92
year olds) whereas using an AP accelerometer Kozey-Keadle et al. reported that
participants were less sedentary on weekend days compared to weekdays (56).
In adolescents, patterns of SB have been mostly identified using selfreported time spent viewing television. The few studies that do exist using
accelerometer measured SB demonstrate mixed results. For example,
Harrington et al. showed no differences in weekday and weekend day SB using
the AP in adolescent females 15-18 years old (38) whereas Jago et al. found
differing amounts of time in SB between week and weekend days in eighth
graders using the Manufacturing Technologies Inc. accelerometer (51). In
addition, they found gender differences by type of SB in that girls tended to
participate in self-care and boys participated in TV electronics. Understanding the
patterns of SB in adolescents in important as the literature consistently
demonstrates a decline in PA during adolescence (18). Based on the conflicting
findings from studies examining patterns of SB in adolescents, further work is
required to understand the variability of accelerometer measured SB in both
adults and adolescents.
There is also a paucity of data regarding the number of days necessary to
reliably estimate SB. Matthews et al. recommends seven days of accelerometer
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monitoring to reliably estimate time spent inactive in adults (68). This would
suggest that studies only using three to five days of data might not be sampling a
sufficient number of days to reliably estimate sedentary time. However, in this
study inactivity was defined as 0-499 activity counts per minute. This count cutpoint is encompassing both light activity and SB and not just SB. Hart et al.
examined the number of days needed to reliably estimate SB using the AG 7164
and using the standard 100 count cut-point. They reported that any five days of
the week reliably predicted total time spent in SB. The outcome for SB in the
study by Matthews et al. and Hart et al. was absolute time spent in SB and does
not account for different wear times. A recent study by Donaldson et al. in adults
19-90 years of age accounts for wear time in the SB outcome variable and they
use various models of the AG. They reported that any four days of SB
measurement provided estimates of SB comparable to the 7-day wear
period (16). Although the study was conducted in younger children (6-8 year
olds), Basterfield et al. also account for wear time in their SB outcome variable.
They found that 3 days of monitoring provided a reliability coefficient of 0.73 for
estimates of percent time spent sedentary using an AG GT1M (6).
The conflicting findings on variability in SB and also the number of days
needed to reliably estimate SB warrants further investigation. This further
investigation should: a) include the use of the AP accelerometer, which is an
accurate and precise measure of SB compared to direct observation (55) b) be
conducted in both adults and adolescents. Therefore, the primary aim of this
study was to examine if day-to-day and week vs. weekend day differences in SB
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exist over a 7-day measurement period. The hypothesis is that there will be no
day-to-day differences in SB over a 7-day measurement period. The secondary
aim was to determine the minimum number of days to reliably estimate 7-days of
SB measurement. The hypothesis is that the minimum number is the same as
that for PA.
Methods
Study Population
Data were accessed from individuals who participated in two research
studies with identical AP wear and processing protocols at the University of
Massachusetts. The two samples were combined to ensure a range of
demographic characteristics such as age and body mass index (BMI). Study
sample one included baseline data from a study examining the changes in
sedentary time and PA in response to an exercise training and/or lifestyle
intervention (54). AP accelerometer data were collected for 7-days from fiftyseven overweight/obese participants. Study sample two included data from a 7day study evaluating the validity of an interviewer administered previous day
recall (71). In this study, AP accelerometer data were collected for 7-days from
adolescents (12–17 year olds; n = 117) and adults (18-70 year olds; n = 102). To
be included in the current study population, participants needed to have seven
valid consecutive days (valid day criteria is described below under SB
Measurement) of AP wear. Of the 270 eligible participants, 106 (62 adults and 34
adolescents) met this 7-day wear criterion. The adults (24 males; 38 females)
were on average 35.8±16.90 years old and overweight (BMI: 28.7±6.16 kg/m2).
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The mean (+/- SD) age of the adolescents (16 males; 18 females) was 14.4±1.35
years old and BMI percentile for the group was at the 63.2 +/- 25.94%.
SB Measurement
Time spent in SB was measured using the AP (AP) (PAL Technologies,
Glasgow, Scotland) accelerometer. The AP is a small (53 x 35 x 7 mm) and light
(20.1 grams) uniaxial accelerometer that uses acceleration and thigh position
(horizontal = lying to sitting, vertical = standing) to estimate time spent sitting,
standing and stepping. Sitting time was characterized as a percent of wear time
spent sedentary (total sitting and lying time divided by total wear time) in order to
account for different wear times. In both studies, participants were instructed to
wear the AP for seven consecutive days on the anterior aspect of the mid-right
thigh during all waking hours, except during water-based activities. The seven
day measurement period began on different days for each participant, thereby
minimizing any order effect. The AP was attached using non-allergenic adhesive
tape. Participants recorded when the device was put on in the morning, removed
at night and any other times the monitor was removed throughout the day.
Participants were shown how to position the device if they had to take it off and
put it back on and were also given a handout with a picture of how to properly
wear the device. AP data were processed using AP proprietary software. The
data from the times the monitor was not worn based on the participant logs were
removed from the analyses. Participants had to have a minimum of 10 hours of
wear time to be considered a valid wear day (94). Participants were only included
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in analyses if they met this valid wear day criterion for all seven consecutive
days.
Statistical analyses
All statistical analyses were performed using R-software (www.rproject.org). Linear mixed effects models were used to compare SB on each day
of the week and determine if there were differences among any of the seven
days. Linear mixed effects models were used to determine if differences existed
between week and weekend days.
To examine if fewer than seven days could be used to predict the mean
SB of the seven days of wear, we randomly sampled one to six days from each
participant. The mean SB from the random samples was compared to the 7-day
mean of SB using linear mixed effects models. Intra-class correlations were also
computed between the estimates from the randomly sampling of one to six days
and the actual 7-day measurement. If the mean from the random samples of
days resulted in an ICC of >0.80 that number of days was considered a reliable
estimate of the seven day SB measurement (73). Statistical significance for all
analyses was p < 0.05.
Results
Day-to-day differences in SB
Figure 1 displays the mean percent of monitored wear time spent
sedentary for each day of the week for adults and adolescents. In adults, SB
ranged from 62.5% (95% CI: 60.6-64.4%) (Saturday) to 67.7% (95% CI: 65.969.5%) (Tuesday) throughout the week. On average the SB recorded on
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Tuesday and Wednesday was significantly higher than Friday, Saturday and
Sunday. The largest difference in sedentary time was found between Tuesday
and Saturday (5.2%) and this difference was significant. The SB recorded on
Thursday was also significantly higher than Saturday. In adolescents, SB was
generally higher than in adults and ranged from 65.9% (95% CI: 64.1-67.7%)
(Sunday) to 68.9% (95% CI: 67.0-70.8%) (Monday) of monitored wear time. In
contrast to the findings in adults, there were no significant differences among any
of the days of the week in adolescents. Figure 2 presents the mean percent of
monitored wear time spent sedentary by type of day (week day vs. weekend day)
for adults and adolescents. In adults, on weekdays SB was significantly higher
(2.3%) compared to weekend days. Contrary to the findings in adults, there were
no differences in SB between weekday and weekend days in adolescents.
Number of days necessary to reliably estimate SB
Figure 3 provides estimates of sedentary time by number of days
sampled in adults. Seven days is considered the ‘truth’ as it is the average of the
seven days the participants actually wore the device. The average of the seven
days indicate that adults spent 65.1% of their monitored time sedentary. The
figure indicates that there are no significant differences in sedentary time when
one to six days are sampled from each participant and the actual SB recorded for
the seven days of monitor wear. The differences in sedentary time from randomly
sampling days to using the actual seven days were minimal (within .18 to .45% of
the seven day measurement). Figure 4 indicates a minimum of two days of
objective monitoring achieved greater than 80% reliability in adults. These
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analyses were repeated where a random weekend day was included in every
estimate for one to six days. The inclusion of a weekend day in the random
samples did not alter the reliability (ICCs range: 0.78 to 0.94).
Figure 5 illustrates estimates of sedentary time by number of days in
adolescents. Based on seven days of monitoring, they spent 67.1% of their time
sedentary. The figure demonstrates that randomly sampling one day produces
significant differences in sedentary time compared to the seven days of
monitoring. The differences in sedentary time from randomly sampling days to
using the actual seven days ranged from 0.01% to 2.9%, which were higher than
the differences found in adults. Figure 6 indicates a minimum of three days of
objective monitoring are necessary to achieve higher than 80% reliability in this
study sample. Similar to observations in adults, the inclusion of a random
weekend day in every estimate for one to six days did not alter the reliability of
the estimates (ICCs range: 0.58 to 0.90).
Discussion
Knowledge regarding the variability and the number of days to reliably
estimate SB is imperative as interest increases in the measurement of this
behavior. One major finding of this study was that there were small significant
differences in AP measures of SB over seven consecutive days in adults who
ranged from 18 to 70 years old whereas there were no significant differences in
adolescents aged 12 to 17 years old. In adults, on average SB was higher on
weekdays compared to weekend days . These findings are consistent with those
of Kozey-Keadle et al. who also used the AP to measure SB in overweight and
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obese office workers (56). These findings are inconsistent with three previous
studies that demonstrated little day-to-day variability in SB (16, 41, 66) and one
previous study that found SB was higher on weekends compared to
weekdays. (100) All four of these studies used the AG to measure SB.
The inconsistent findings with the other studies could be due to different
measurement tools (AP vs. AG) and that the AG is not sensitive enough to detect
differences in SB. Another reason for inconsistencies could be the study
samples. In the study by Kozey-Keadle et al., the participants were recruited
based on being overweight and obese whereas the other study samples were
not. Additionally, in the study by Donaldson et al. that found SB to be stable over
all days of the week, they stated that the participants included in their study had
significantly lower body mass indices than those who were excluded, warranting
more investigation in SB variability in overweight and obese populations.
Therefore, we also examined SB variability stratified by weight status (body mass
index in adults and body mass index percentile in adolescents). and completed
the same analyses. Separate analyses were conducted for adults and
adolescents and we found that SB was higher on weekdays than weekend days
in the overweight adults (Figure 7) and adolescents (Figure 8) but not in the
normal weight adults and adolescents. Thus, the pattern of SB may be different
in overweight/obese individuals compared to those of normal weight status.
Currently, the clinically meaningful change in SB needed to reduce the risk
of negative health outcomes is unknown making the overall differences of 2.3%
(~22 minutes based on mean wear time) between weekdays and weekend days
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in adults difficult to interpret in this context. Our other main finding that a
minimum of two days of sampling produced an ICC greater than 0.90 in adults
and that the inclusion of a weekend day does not change this result would lead
us to believe that this difference is minimal. However, based on our findings
when the data was stratified by overweight/obese versus normal weight it may be
important to include a weekend day if the study sample includes mainly
overweight or obese individuals. Despite no day-to-day differences in SB in
adolescents, a minimum of three days of sampling was necessary for an ICC
greater than 0.80 and the inclusion of a weekend day did not change this result.
We had information on whether the adolescents were in school or not
during the 7-days of monitoring. Therefore, we also stratified our adolescent
population based on whether the participant indicated they were in school or not
during the study period (Figure 9). While this did not change our overall results, it
did show that SB was more variable (based the 95% confidence intervals) in
adolescents who were not in school compared to those in school. However, we
only had 11 participants who were not in school during this time. Therefore,
determining if a participant is in school or not affects the variability of SB warrants
further investigation. It is possible that studies that seek to measure SB in
children not in school (e.g., during summer vacation) may need more days of
measurement.
While we need to be cautious in our cross-study comparisons as NHANES
utilizes the AG to measure SB, the adults in our present study sample spent
more time in SB than a nationally representative sample from NHANES. Our
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sample spent an average of 65% of their monitored time sedentary whereas
those in NHANES spent an average of 55% in sedentary time (69). Our data
more closely resemble those of Donaldson et al. whose participants were
sedentary for an average of 64% of the time based on the AG. While Donaldson
et al. found no day-to-day differences and our differences were minimal, the
higher percentage of time spent sedentary in both these cohorts may be an
important factor to consider. Therefore, our results that indicate a minimum of
two days can reliably estimate seven days of SB may not be applicable to a
study population that is less sedentary.
A major strength of the current study is the use of the AP, to assess
sedentary behavior. Another strength is that we included adults with a wide age
range (18-70 years) and adolescents (12-17 years). In addition, we utilized a
unique analysis approach by randomly sampling one to six days from each
participant and comparing to the seven day estimate using linear mixed models.
However, this study is not without limitations. Our sample size may be biased as
inclusion criteria only included participants who had seven consecutive days of
data. We also did not have specific information about employment status in the
adults and, therefore, did not account for that in our analyses.
In conclusion, there were small, but significant differences in SB among
days of the week in adults. However, this still resulted in only needing two days
of wear to reliably estimate 7-days of SB. In adolescents, there were no day-today differences and a minimum of 3 days of wear was necessary for 80%
reliability. The minimum wear of two and three days rather than the typical 7 day
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period has important implications at the analysis level. If SB is the variable of
interest, it is possible that more participants could be included in analyses if only
two or three days of data are necessary for reliably estimating SB. However,
more research is still needed to determine how particular characteristics (e.g.,
employment status,) affect the variability of SB.

Figure 1. ActivPAL measures of percent of monitored time spent sedentary
for each day of the week
Data presented as mean and 95% confidence intervals
Circles indicate weekdays; Squares indicate weekend days
* indicates significantly different than Friday (p<0.05)
#
indicates significantly different than Saturday (p<0.05)
$
indicates significantly different than Sunday (p<0.05)
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Figure 2. ActivPAL measures of percent of monitored time spent sedentary
for week days vs. weekend days
Data presented as mean and 95% confidence intervals
* indicates significantly different (p<0.05)
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Figure 3. Estimates of sedentary time based on how many number of days
were randomly sampled from each adult
Data presented as mean and 95% confidence intervals
Note: 7 days is considered the truth as it is the actual number of days the monitor
was worn
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Figure 4. Estimates of sedentary time based on how many number of days
were randomly sampled from each adolescent
Data presented as mean and 95% confidence intervals
Note: 7 days is considered the truth as it is the actual number of days the monitor
was worn
* indicates the estimate was significantly different from the average sedentary
time of the seven days of monitor wear
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Figure 5. Agreement between percent of time spent sedentary for the seven
days of measurement and a randomly sampled number of days (1-6 days)
for adults
The diagonal line represents the line of identity; if dots line up on line there was
perfect agreement

45

Figure 6. Agreement between percent of time spent sedentary for the seven
days of measurement and a randomly sampled number of days (1-6 days)
for adolescents
The diagonal line represents the line of identity; if dots line up on line there was
perfect agreement
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Figure 7. ActivPAL measures of percent of monitored time spent sedentary
for each day of the week by BMI Status (overweight. vs normal weight) in
adults
Data presented as mean and 95% confidence intervals
Circles indicate weekdays; Squares indicate weekend days
* indicates significantly different than Friday (p<0.05)
#
indicates significantly different than Saturday (p<0.05)
$
indicates significantly different than Sunday (p<0.05)
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Figure 8. ActivPAL measures of percent of monitored time spent sedentary
for each day of the week by BMI Status (overweight. vs normal weight) in
adolescents
Data presented as mean and 95% confidence intervals
Circles indicate weekdays; Squares indicate weekend days
* indicates significantly different than Sunday (p<0.05)
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Figure 9. ActivPAL measures of percent of monitored time spent sedentary
for each day of the week by school status (in school vs. not in school
during measurement period) in adolescents
Data presented as mean and 95% confidence intervals
Circles indicate weekdays; Squares indicate weekend days
* indicates significantly different
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CHAPTER IV
STUDY TWO - A LONGITUDINAL ASSESSMENT OF ACCELEROMETER
MEASURED PHYSICAL ACTIVITY AND SEDENTARY BEHAVIOR IN ADULTS
WITH OSTEOARTHRITIS
Introduction
Osteoarthritis (OA) affects approximately 27 million American adults and
this prevalence is anticipated to increase considerably due to increases in
obesity and the aging of our population (48, 58). In other chronic diseases, there
are established methods to diagnose and determine how the disease is
progressing over time. However, there is no consensus in the literature regarding
a single symptom or test to diagnosis or monitor progression of OA (3). Currently,
one way to assess symptoms and/or progression of the disease is by monitoring
a patient’s functional ability, or the ability to carry on normal daily activities.
Physicians can assess a patient’s functional ability using self-reported
questionnaires (e.g., Western Ontario & McMaster Universities Osteoarthritis
Index (WOMAC)) or by objective functional performance measures (e.g., timed
20-meter walk, chair stand test) (65). While self-report provides information on
perceived ability and the objective functional performance measures provide
some information on actual ability, they do not necessarily reflect a patient’s
functional status in everyday living (76). Therefore, they may not provide
physicians information on the impact of OA on daily function or treatment
effectiveness.
Wearable devices such as accelerometers have the capability of
measuring free-living behavior. Accelerometers provide reliable, objective
measures of physical activity (PA) and sedentary behavior (SB). Free-living PA
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and SB metrics from accelerometers may provide physicians and other health
care professionals more information that comprehensively characterizes
individual function and how OA patients are affected in their daily life by
symptoms of OA. For example, accelerometer-measured PA is reportedly related
to improved physical function (13). SB also affect physical function in those with
OA.
Some of the first work examining SB in relation to function in those with
OA comes from the Osteoarthritis Initiative (OAI). The OAI is a cohort study of
community-dwelling adults with or at high risk for knee OA (60). Accelerometer
data (ActiGraph (AG) GT1M) was collected on a sub-sample of the
participants (60). In a cross-sectional analysis in the sub-sample, Lee et al. report
that more sedentary time was related to reduced physical function (59).
Therefore, PA/SB metrics may be useful in tracking the progression of the
disease over time, as they are potential measures of natural functional capacity.
Yet, before accelerometer technology is consistently implemented in a
clinical setting, it is necessary to collect objectively measured PA and SB in OA
patients as the disease progresses. Accelerometer data collected longitudinally
can be used to quantity natural changes in these PA/SB metrics as the disease
progresses, which will help to develop appropriate PA and SB guidelines in this
population. Examining the relationship between these PA/SB metrics and pain
and function will inform the development of future interventions designed to
maintain physical function in these patients. It is possible that changes in SB may
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be a more feasible goal and better suited for the OA population than changes in
PA.
In another analysis in the sub-sample with accelerometer data from the
OAI, it was found that baseline SB was related to subsequent functional loss
providing some longitudinal information on SB and function (85). However, in
addition to collecting data longitudinally, another methodological consideration is
the type of accelerometer that is utilized. Since SB is particularly important in an
OA population, using a monitor that has the capability of accurately measuring
this behavior is important. The Osteoarthritis Initiative (OAI), which is a multicenter observational study of men and women with OA utilize the AG
accelerometer to measure PA and SB. The AG has been shown to be less
sensitive for measuring changes in SB (55). Our lab has previously demonstrated
the activPAL (AP) is an accurate and precise measure of SB and is sensitive
enough to detect changes in SB as compared to direct observation (55). To our
knowledge, few published studies exist that use the AP in patients with OA (63,
93) and in one of the published studies with the AP, only activity metrics from the
monitor are presented (93). In the other study, SB is presented as hours spent
lying or hours spent sitting/standing (63). The ability of the AP to accurately and
precisely measure SB along with its ability to detect changes in this behavior
makes it appealing to use in a longitudinal study. Therefore, the first aim of this
study was to determine if there are changes in PA and SB assessed with the AP
accelerometer during the natural progression of knee hip OA over a nine month
period. We hypothesized that PA would decrease and SB would increase over
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the 9-month period. The second aim was to determine if AP accelerometer
measures of PA and SB are related to patient reported pain and function at each
time-point. We hypothesized that the AP measures of PA and SB would be
related to patient reported pain and function at each time-point.
Methods
Study Population
Participants were recruited from the Arthritis and Total Joint Center on the
University of Massachusetts Medical School campus. All patients with knee pain,
stiffness, and mobility impairment due to OA were eligible to participate in this
study. Participants who planned on surgical intervention (e.g., knee or hip
replacement) during the 9-month study period were not eligible to participate.
Additional exclusion criteria included: pain and mobility issues unrelated to their
OA, or use of assistive devices during locomotion.
Patients were invited to participate via mail and with a follow-up phone call from a
research nurse. If the participant was interested in enrolling in the study, the
research nurse scheduled the first visit to the clinic.
Study Design
The study design is pictured in Figure 10 and a description of the study
visits are described below.
Visit 1 (Baseline)
Participants came to the Arthritis and Total Joint Center at the University
of Massachusetts Medical Center. They read and sign an informed consent
document that was approved by the University of Massachusetts Medical
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School’s Institutional Review Board. Participants completed the WOMAC to
assess self-reported pain, stiffness and physical function. A research nurse
recorded participant height and weight. In addition, the nurse provided detailed
instructions on how to wear the AP accelerometer and how to properly record
information when the monitor was put on for the morning, taken off for the
evening and any other times the device was removed during the day. The AP
was worn for a total of 7-days in the participant’s free-living environment. The
nurse provided the participant with mailing materials to send back the monitors
after the completion of the 7-day wear period. The participant was contacted at
one point during the 7-day wear period to insure participant compliance with the
devices and answer any questions from the participant.
Visit 2 (3-months), Visit 3 (6-months), Visit 4 (9-months)
Three, six, and nine months after baseline, the participant returned to the
clinic. The same diagnostic protocol as described for Visit 1 was completed at
each visit.
Measurement of PA and SB
Participants wore an AP accelerometer to estimate free-living PA and SB.
The AP (PAL Technologies, Glasgow, Scotland) is a small (53 x 35 x 7 mm), light
weight (20.1 g) device that attaches to the skin on the anterior mid-thigh. Based
on acceleration and position of the thigh the device estimates time spent time
spent sitting, standing, and stepping. This device was chosen as the
measurement tool as a study conducted by Kozey-Keadle et al. established that
it is valid for measuring SB in a free-living environment (55). This study also
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showed that the device can detect changes in SB whereas an AG GT3X worn on
the hip was not sensitive to detect changes (55). The ability to detect changes in
SB is important for the aims of this current study, and therefore, supports the use
of the AP as our measurement device.
The event files from the AP proprietary software were used to determine
the following PA/SB metrics for each participant:
1. Percent of time spent sedentary: total sedentary time divided by total wear
time
2. Break rate: number of breaks per sedentary hour
3. Percent of time spent standing: total standing time dividing by total wear
time
4. Percent of time spent stepping: total standing time dividing by total wear
time
5. Percent of time spent in light activity: total time in light activity divided by
total wear time
6. Percent of time in MVPA: total time in MVPA divided by total wear time
7. Breaks per day (count): number of times there was a transition from SB
8. Total time in guideline minutes: total time spent in minutes of MVPA that
qualify toward meeting the PA guidelines, defined as a greater or equal to
10–minute bout, allowing up to a 2-minute interruption
9. Number of guideline bouts: number of bouts of activity that quality towards
meeting the guidelines, defined as > 10 minutes of MVPA, allowing up to a
2-minute interruption
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10. Steps per day: sum of total steps per day
Measurement of self-reported pain and function
The WOMAC is a 24 item self-report tool used to assess pain, stiffness
and physical function in patients with OA. Each response is based on a 5 point
Likert scale. Typically a lower score indicates less pain, stiffness and physical
function. However, these data were transformed to normalize the WOMAC data
to percentages of 0 (worse) to 100 (best), which allows for comparisons with
other physical functional measures used in the literature (5). This questionnaire
has been shown to be valid (82) and reliable (8).
Data Cleaning
Only data from patients who had valid AP data at all four time-points
(baseline, 3-months, 6-months and 9-months) were included in these analyses.
Ten hours of wear was required for a day to be considered valid and four-valid
days defined a valid wear period (94). Of the 50 patients that were enrolled at
baseline, 36 had valid data at all four time-points.
Statistical Analyses
All statistical analyses were performed using R-software packages
(www.r-project.org). Differences in the PA/SB variables at each time point
compared to baseline were analyzed using linear mixed models with random
subject specific effects. To determine the relationship between SB and PA
variables and WOMAC scores a linear regression model was employed for each
time-point. The relationships were established using the R2 value from the linear
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model and the p-value was set to <0.05 to determine if the relationships were
significant.
Results
Thirty-six patients (23 females/13 males) had valid AP data at all four
time-points and the mean (+/- SD) age was 58.1 ± 7.62 years old and BMI was
34.3 ± 7.56 kg/m2.
Longitudinal changes in SB and PA variables
Table 1 presents the longitudinal data for all SB and PA variables
measured in this study using the AP. Three participants were scheduled for a
total joint replacement during the study period, which was an exclusion criterion
for continued participation. Four participants withdrew from the study; three due
to difficulties with the commute to the hospital and one who sought care from
another provider. Lastly, we were unable to collect six or nine month data on six
participants due to the timing for the study protocol. No participants were lost due
to not meeting valid day criterion.
The 36 participants that were included in these analyses did not have any
significant changes in any of the SB variables at any time-point in the study.
Participants were on average sedentary for 62.7 to 65.2 percent of wear time
throughout the study with the lowest recorded sedentary time at 3-months and
the highest at 9-months. The difference between the highest and lowest
sedentary time is minimal and equates to a 24 minute per day increase over a
16-hour waking day. In addition to the sedentary variables, the percent of time
spent standing did not change over the 9-month period. There were, however,
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significant changes in all of the activity variables at each time-point compared to
baseline with the exception of % stepping which was significantly lower at 6months and 9-months, but not at 3-months. Guideline mins, guideline bouts, and
steps per day were all significantly lower than baseline at each subsequent time
point.
Table 2 illustrates how time spent in different intensities (sedentary, light
and moderate-to-vigorous) changed over the 9-month study. There were no
significant changes at any time-point for percent of time spent sedentary or in
light activity. There were, however, significant decreases from baseline in percent
of time spent in MVPA at each subsequent time-point. . The pattern of changes
mentioned previously for time spent in different intensities is similar to the
findings for time spent in different postures (sitting/lying, standing, and stepping).
Relationship between SB and PA variables with self-reported pain and
function
The relationship between the SB and PA variables from the AP and the
self-reported pain and function from the WOMAC were examined using three
different approaches. First, at each time-point (baseline, 3-month, 6-month, and
9-month) the relationship between the SB or PA variable of interest and the
WOMAC score was determined. The R2 values describing the relationship
between the SB variables and the WOMAC were all low (range: 0 to 0.13) and
mostly non-significant. The only statistically significant relationship found was
between SB break-rate and WOMAC at 3-months (R2 = 0.13, p = 0.03). Figure
11 illustrates how the break-rate variable is related to the WOMAC score at
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baseline, 3-months, 6-months and 9-months. Figures illustrating the relationship
between the other SB variables and the WOMAC can be found in Appendix B.
Similar to the SB variables, the R2 values describing the relationship between the
PA variables and the WOMAC were all low (range: 0 to 0.14) and mostly nonsignificant. The only significant relationships with the WOMAC were for % of time
spent in light activity (R2 = 0.12, p = 0.04) and standing (R2 = 0.14, p = 0.03) at 6months. ). The higher WOMAC score was associated with lower light and
standing activity. Figure 12 illustrates how the % of time spent standing variable
is related to the WOMAC score at baseline, 3-months, 6-months and 9-months.
Figures that illustrate the relationship between the other PA variables and the
WOMAC are presented in Appendix B.
The second approach used to analyze the data was to determine whether
the change in WOMAC score since baseline was related to any of the SB and PA
variables at 3-months, 6-months and 9-months. This did not improve the
relationship between the AP measured variables and the WOMAC. The R2
values ranged from 0 to 0.02 and there were no significant relationships. Figure
13 presents an example of these low relationships. It illustrates the relationship
between percent of time spent sedentary and the change in WOMAC score since
baseline at 3-months, 6-months and 9-months.
The third approach for data analysis was to determine whether the change
in WOMAC score since baseline was related to the change in any of the SB and
PA variables since baseline at each time-point. The R2 values remained low (0 to
0.11) and did not yield any significant relationships using this third approach.
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Figure 14 demonstrates an example of these low relationships. It illustrates the
relationship between change in steps per day and the change in WOMAC score
since baseline at 3-months, 6-months and 9-months.
Discussion
In order to optimize care in patients with OA, it is important to understand
how their disease is affecting everyday life. Use of wearable sensor technology
offers an option to quantify PA and SB and changes in these behaviors as
alternative objective measures of function in the free-living environment. One
major finding from our longitudinal data was that there were no significant
changes in any SB metrics over the 9-month period. In contrast to the SB metrics,
there were significant declines from baseline at each time-point in all of our
activity metrics with the exception of standing. Various randomized controlled
trials PA programs have shown to provide substantial benefits to individuals with
OA including improved function (24, 78, 79). Therefore, the declines in PA
variables over time is concerning and support the need to strengthen public
health efforts to increase activity in adults with OA.
This present cohort of individuals with OA were found to be sedentary 6265% of time depending on which time-point was examined. This sedentary time
is 7-10% higher than similarly aged (non-OA) individuals in the NHANES
cohort (69), but similar to findings from the OAI (89). Participants in the OAI were
also found to be largely inactive, spending about 67% of their monitored time
sedentary (89). However, caution in cross-study comparisons is needed as both
SB data from NHANES and the OAI were collected using the AG accelerometer
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and a cutpoint of <100 counts∙min-1 defined the activity count threshold for
sedentary time
The PA guidelines are based on time spent in activities of moderate-tovigorous intensity lasting 10 minutes or longer. At baseline, our participants were
on average participating in 17.6 minutes of these bouts of activity per day and
less than this at each subsequent time point. Our baseline findings are slightly
higher than the averages found in OAI cohort (9.2 minutes for men; 5.4 minutes
for women), but similar at each subsequent time-point. Collectively, the evidence
from the OAI and our current study confirm that as in other chronic conditions,
adherence to an active lifestyle is low in populations with OA. This is potentially
compounded in individuals with OA for two reasons. One, participants with OA
may believe that exercise could exacerbate their symptoms. Two, they may
already have experienced pain while exercising with OA. The Chronic OA
Management Initiative recently suggested that outcomes for patients with OA
could be improved by increasing efforts to implement non-pharmacological
treatement modalities when appropariate, which includes PA (77). Participants in
our study had no change in SB, decreases in stepping behavior, but no change
in standing behavior. Therefore, a potential approach to managing OA could be
to replace sitting activities with standing activities or those of light intensity.
Attempting to increase standing/light activity first, and gradually incorporating
increases in moderate-to-vigorous activity (MVPA) may be more manageable
and improve self-efficacy for PA (72) than trying to incorporate MVPA to their
current activity levels.
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In our study, the relationships found between PA/SB metrics and
pain/physical function at all time-points were very weak to non-existent. This is in
contrast to findings by Semanik et al. from the OAI (85) that used baseline
accelerometer measures of SB and found that being less sedentary at baseline
was related to less functional loss at their two year follow-up in participants at risk
or currently diagnosed with knee OA. Their functional loss measures were based
on gait speed and chair stand rate. However, also using data from the OAI, Liu et
al. found that accelerometer measured PA was not associated with 1-year patient
reported symptom improvement in this same population. Similar to our study, in
the analysis by Liu et al., they utilized the WOMAC to measure patient reported
symptoms (61). Therefore, it is possible the very weak relationships found in our
study and in the analysis by Lie et al. could be due to the nature of self-reporting
pain and function. There may have been misclassification and/or differential
errors in reports of pain and function that would attenuate these relationships. In
addition, the wearable sensor technology may be assessing different constructs
of function compared to patient reports. This has been noted when comparing
self-reported and objectively measured PA (42). It has been shown that selfreporting PA can capture some aspects of PA that objective measures cannot
(e.g., location, context) and vice versa. Patient reports of functional status may
be reflecting perceived ability and may be influenced by certain characteristics
such as previous experiences, pain tolerance, and psychological factors whereas
objective measures of function may be reflecting actual ability and can be
influenced by features such as motivation and fatigue (99).
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Another contributing factor to the weak relationships between PA/SB
metrics and patient reported symptoms is that it has also been suggested that
the WOMAC itself has limitations. Alviar et al. suggest that patient-reported
outcome measures such as the WOMAC do not ask questions about certain
areas of activity that may be important to one’s pain and function (4). It is
possible had we utilized a different self-report tool or a more objective measure
of pain/function, we may have found significant relationships. It is also important
to note that in our study of 36 participants, patient-reported pain and function
from the WOMAC remained stable over the 9-month study period. The average
WOMAC score was 69 at baseline and did not significantly change from one time
point to the next. This may explain why we did not find any relationships when we
examined whether the change in WOMAC score since baseline was related to
any of the SB and PA variables at 3-months, 6-months and 9-months.
The study has some important strengths. First, the PA/SB metrics were
measured longitudinally over a 9-month period allowing us to characterize natural
changes in these metrics in OA patients undergoing conservative, non-surgical
treatments. The temporal measurement of these metrics is important, as this
disease is progressive (74). Second, the AP was the device chosen to measure
PA and SB. This device has been validated for accurately and precisely
measuring SB (55) as well as being able to discriminate SB from standing and
stepping (39). In addition, the AP is sensitive enough to detect changes in
SB (55), which was essential to the first aim of our study. The device also allows
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characterization of different features of SB and PA (e.g., breaks from SB,
standing activity).
The study also has some limitations. The study sample was limited to 36
of the original 50 participants who had AP data at all four time-points. The study
population was 100% Caucasian and included individuals who were being
conservatively treated (e.g., physical therapy, injections) for OA, so we cannot
generalize this to all OA patients (e.g., those who receive surgery). We also did
not have detailed information on the timing of when we collected PA/SB
measures relative to when the patients may have received cortisone injection,
pain medication, or physical therapy.
In conclusion, this study produced the first objective, longitudinal PA/SB
metrics using the AP in adults with OA. The findings suggest that SB was stable
over nine months in adults with OA. However, there were significant declines in
PA. These data inform the literature that interventions to help individuals maintain
their PA levels are warranted. Future studies should also include both subjective
and objective measures of function and determine how they relate to PA/SB
metrics and collect data on how. Future studies should also examine how these
PA/SB metrics respond to different treatment options. It is possible PA/SB
metrics may be used as an outcome assessment to quantity success of
treatments for OA.
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Patient sees orthopedic doctor
for first time

Non-operative management of
hip or knee OA is decided

Patient mailed invitation to
participate w/ phone follow-up

Patient declines –
No further contact

Patient agrees to
participate

9 month period

Baseline

3

6

9

7-days
Measurements at each time
point:

AP Wear

WOMAC, BMI

Figure 10. A schematic of the study design and measures at each timepoint (baseline, 3-month, 6-month, and 9-month)
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% Sedentary
Breaks Per
Day
Break-Rate
% Standing
% Stepping
Guideline
Mins
Guideline
Bouts
Steps Per
Day

Baseline

3-Month

6-Month

9-Month

63.7±1.64

62.7±1.03

63.9±1.02

65.2±1.04

48.5±1.87

46.9±1.23

46.7±1.22

48.7±1.24

5.4±0.24
26.7±1.38
9.6±1.64

5.3±0.18
28.3±0.83
9.0±1.03

5.3±0.17
27.3±0.82
8.8±1.02*

5.5±0.18
25.9±0.83
8.9±1.04*

17.6±2.14

10.1±2.15*

11.7±2.14*

10.3±2.15*

0.87±0.09

0.63±0.09*

0.69±0.09*

0.63±0.10*

6547±375

5761±377*

5784±375*

5658±377*

Table 1. AP measures of PA and SB at each time-point
Data presented as mean ± SE
Note: % Sedentary, % Standing, and % Stepping are expressed as a percent of
monitored wear time. Data includes 36 participants with valid data at all timepoints.
* indicates the variable at that time-point was significantly different from baseline
(p<0.05)

% Sedentary
% Light
% MVPA

Baseline

3-Month

6-Month

9-Month

63.7±1.64
30.4±1.45
5.9±0.34

62.7±1.03
32.1±1.46
5.2±0.34*

63.9±1.02
30.9±1.45
5.2±0.34*

65.2±1.04
29.6±1.46
5.2±0.34*

Table 2. Measures of percent of time spent in sedentary, light and MVPA at
each time-point
Data presented as mean and 95% confidence intervals
Data includes 36 participants with valid data at all time-points.
% sedentary = percent of monitored wear time spent sedentary
% light = percent of monitored wear time spent in light activity
% MVPA = percent of monitored wear time spent in moderate-to-vigorous
physical activity
* indicates the variable at that time-point was significantly different from baseline
(p<0.05)
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Figure 11. Relationship between break rate (# of breaks per sedentary hour)
and the WOMAC at each time-point
Data includes 36 participants with valid data for all four time-points
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Figure 12. Relationship between percent of time spent standing and the
WOMAC at each time-point
Data includes 36 participants with valid data for all four time-points

Figure 13. Relationship between percent of time spent sedentary and the
changes in WOMAC score since baseline at each subsequent time-point
Data includes 36 participants with valid data for all four time-points
68

Figure 14. Relationship between changes in steps per day and changes in
WOMAC score since baseline at each subsequent time-point
Data includes 36 participants with valid data for all four time-points
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CHAPTER V
STUDY THREE – MONITOR TYPE AFFECTS ACTIVITY AND SEDENTARY
BEHAVIOR ESTIMATES IN PATIENTS WITH OSTEOARTHRITIS
Introduction
There are large volumes of accelerometer measured physical activity (PA)
and sedentary (SB) data in healthy adults from epidemiological studies such as
the NHANES and BRFSS (22, 69, 94). These data are helpful and applicable for
making judgments about the PA and SB habits of the general population, but
may not pertain to specific clinical populations. However, measuring PA and SB
in clinical populations with mobility limitations may be particularly important, as
they may be more likely than the general population to adopt a sedentary
lifestyle. Therefore, they may be at higher risk for developing co-morbidities that
are associated with a sedentary lifestyle (21). Individuals with OA, a degenerative
joint disease caused by the breakdown of cartilage in one or more joints, is an
example of such a population.
The majority of studies examining activity behavior in OA patients have
relied heavily on self-report. Self-reporting of activity behavior is a method that
has been shown to have inadequate reliability and validity compared to more
objective methods (e.g., accelerometers) (80). However, due to technological
advancements, accelerometers have become more ubiquitous (95) and are
being used to measure activity behavior in individuals with OA (19, 27). Despite
the known benefits of PA on symptoms of OA (24, 78, 79), only 12.9% of men
and 7.7% of women with knee OA from the Osteoarthritis Initiative (OAI) met the
2008 PA Guidelines using accelerometry as the tool to assess PA behavior (19).
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The low prevalence of individuals with OA participating in PA is unfortunate as
higher levels of PA have been shown to be related to improved physical function
in individuals with OA whose PA has been measured using accelerometers (13).
The focus of current PA interventions in those with OA has been mostly on PA
behavior only. However, while data are limited, SB also appears to be important
in those with OA. Using an ActiGraph (AG) in a sub-sample from the OAI, Lee et
al. reported less time spent in SB was associated with improved physical function
in adults with knee OA and this was independent of time spent in MVPA (59).
While the use of accelerometers in patients with OA is certainly an
advancement, a current concern is whether results from studies that use different
accelerometers are comparable. In recent years, the activPAL (AP) has been
more widely used for the measurement of SB as it is has been shown to be more
accurate and precise than the AG for estimating SB in the free-living
environment (53). The AP’s accuracy, precision, and ability to measure time
spent in different postures (sitting/lying, standing/stepping) as well as time spent
in different intensities (sedentary, light and MVPA) make this device attractive to
researchers (32, 84).
Previous work from our lab examined the accuracy of two SB cut points
from the AG (100 and 150 counts per minute) compared to the AP (56). The 100
counts∙min-1 (AG100) was more accurate than the 150 counts∙min-1 (AG150)
when using the AP as a criterion. Because this previous work was conducted in
those without a musculoskeletal disorder, it is not known if similar findings will be
observed in a sample of OA patients. If differences between AP and AG
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estimates of PA/SB do exist, this will have implications for comparing activity and
SB measures across studies that use different monitors. In addition, differences
in monitor output may impact the relationships between activity behavior and
symptoms of OA (e.g., pain and physical function). Therefore, the primary aim of
this study was to determine if the AG and AP provide comparable estimates PA
and SB in a sample of patients with OA. The secondary aim of this study was to
compare the relationships between patient-reported pain and function and PA/SB
measures from the AP and AG accelerometers.
Recently, we collected data to quantify changes in objectively measured
PA and SB using an AP and AG during the natural progression of OA at baseline
(initial clinic visit to treat OA), 3, 6, and 9 months, and to correlate these PA/SB
metrics with patient-reported changes in pain and function. Baseline measures
from this longitudinal study were used to address this current study’s aims.
Methods
Study Population
Potential participants were recruited from the Arthritis and Total Joint
Center on the University of Massachusetts Medical School campus. Eligible
participants were 21-75 years of age, had knee pain, stiffness and mobility
impairment due to their OA, and their condition was being conservatively (e.g.,
not planning on undergoing operative treatment). Exclusion criteria included if
they were planning on surgical intervention within 9-months, had pain and
mobility issues unrelated to their OA, or used assistive devices to get around as
they may impact accelerometer data. Only baseline data were used for these
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current analyses, and therefore only procedures pertaining to baseline will be
outlined below.
Baseline Visit
Participants were invited to participate via mail and with a follow-up phone
call from a research nurse. Participants went to Arthritis and Total Joint Center
on the University of Massachusetts medical campus for their baseline visit. They
read and signed the approved informed consent document. Participants filled out
the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) to
assess their self-reported pain, stiffness and physical function. A research nurse
recorded the participant’s height and weight. In addition, the nurse provided
detailed instructions on how to wear the AP and AG accelerometers and how to
fill out the monitor log to indicate when the monitors were put on for the morning,
taken off for the evening and any other times they may have been removed
during the day. The AP and AG were worn for 7-days in the participant’s freeliving environment. The nurse also provided the participant with mailing materials
to send back the monitors after the completion of the 7-day wear period. The
participants were contacted one time during the week of monitor wear to check
on patient compliance and answer any questions or concerns by the participant.
Measurement of PA and SB
Participants wore two accelerometers to measure free-living PA and SB.
The first device was an AP (PAL Technologies, Glasgow, Scotland). The AP is a
small (53 x 35 x 7 mm), light weight (20.1 g) device that attaches to the skin on
the anterior mid-thigh. Based on acceleration and position of the thigh the device
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estimates time spent time spent sitting/lying, standing, and stepping. The AP has
been established as valid for measuring SB in a free-living environment
compared to direct observation (55). SB time (sitting plus supine postures) from
the AP is estimated from AP algorithms provided in the software platform using
the event files. MET values from the AP file using time in an upright posture
were used to determine time spent in light and moderate-to-vigorous activity.
The AG GT3X (AG) (ActiGraph LLC, Pensacola, FL) was also worn over
the monitoring period and this device is a small (1.5 x 1.44 x 0.7 inches) and light
(28 grams) triaxial accelerometer that was worn on an elastic belt over the right
hip. The monitor was initialized to record accelerations in one-second epochs.
SB from the AG was considered the sum of the minutes where the monitor output
was below 100 counts∙min-1 (AG100). In addition, we examined SB using the
threshold of 150 counts∙min-1 (AG150). The Freedson cut-points were applied to
determine time spent in light and moderate-to-vigorous (29).
The following PA and SB metrics were determined from each monitor:
1. Percent of time spent sedentary: total sedentary time divided by total wear
time
2. Percent of time spent in light activity: total time in light activity divided by
total wear time
3. Percent of time in MVPA: total time in MVPA divided by total wear time
4. Breaks per day (count): number of times there was a transition from SB
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5. Total time in guideline minutes: total time spent in minutes of MVPA that
qualify toward meeting the PA guidelines, defined as a > 10–minute bout,
allowing up to a 2-minute interruption
6. Number of guideline bouts: number of bouts of activity that quality towards
meeting the guidelines, defined as > 10 minutes of MVPA, allowing up to a
2-minute interruption
7. Steps per day: sum of total steps per day
Measurement of self-reported pain and function
The Western Ontario and McMaster Universities Arthritis Index (WOMAC)
is a self-report tool used to assess pain, stiffness and physical function that is
specific to knee/hip OA. There are 24-items in this questionnaire that assess 3subscales (pain, stiffness, physical function). Each response is based on a 5
point Likert scale. Typically a lower score indicates less pain, stiffness and
physical function. However, these data were transformed to normalize the
WOMAC data to percentages of 0 (worse) to 100 (best) (5). This questionnaire
has been shown to be valid (82) and reliable (8).
Data Cleaning
Only data from patients that had valid data from the both the AG and AP
for the same time periods at baseline were included in these analyses. Ten hours
of wear was required for a day to be considered valid and four-valid days were
required defining a valid wear period (94). Of the 50 patients that were enrolled at
baseline, 33 had valid data that met these criteria for both monitors.
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Statistical Analyses
All statistical analyses were performed using R-software packages
(www.r-project.org). To determine if there were differences among the output
from each the AP, AG100, and AG150 a linear mixed effects model was used for
each variable of interest. To determine the relationship between SB and PA
variables and WOMAC scores a linear regression model was employed. The
relationships were established using the R2 value from the linear model and the
p-value was set to <0.05 to determine if the relationships were significant.
Results
The 33 participants who were included in the analyses were 57.9 ± 7.87
years old (mean +/- SD) and BMI was 34.4 ± 7.84 kg/m2.
Comparison of estimates from the AP, AG100, and AG150
Table 2 shows the mean ± standard error for SB and PA metrics that were
compared among the AP, AG100 and AG150. The AG150 estimated significantly
more sedentary time than the AP and AG100 by 6% and 5%, respectively. The
breaks per day from the AG100 and AG150 were both significantly lower than
that recorded by the AP. Similarly, steps per day were also significantly lower for
the AG100 and AG150 compared to the AP. The AG100 estimated significantly
more steps than the AG150. When activity is summarized as average guidelines
minutes or number of guidelines bouts, there were no significant differences
among the AP, AG100 and AG150.
Figure 15 illustrates monitor differences in percent of time spent in
sedentary, light and MVPA. As stated previously, only the AG150 was
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significantly different than the AP for percent of time spent sedentary. The AG100
recorded more and the AG150 less light activity than the AP. The AG100
recorded significantly more light and MVPA time than the AG150. However, both
the AG100 and AG150 recorded less MVPA than the AP.
Comparison of WOMAC and accelerometer-measured PA and SB
associations with the AP and AG
There were no differences in the relationships found by monitor type and
measure (AP, AG100, or AG150) between SB and PA variables and the patient
reported pain and function from the WOMAC. Figure 16 presents the percent of
time spent in sedentary, light, and MVPA in relationship to WOMAC scores at
baseline from each of the monitors (AP, AG100, and AG150). The R2 values
were all zero for percent of time spent in SB and light activity for the AP, AG100
and AG150. In addition, the R2 values are all low 0.05 to 0.07 for percent of time
spent in MVPA for the AP, AG100 and AG150. These findings are consistent for
all PA and SB variables examined. Figures illustrating the consistent non-existent
relationships with the WOMAC for additional SB/PA variables from the monitors
are shown in Appendix C.
Discussion
As the number of studies that measure PA and SB using accelerometers
in OA patients increase, it is imperative we understand how the estimates from
these devices compare. One major finding from the current study is that there are
differences in estimates of SB metrics (% of time spent sedentary and breaks per
day) among the AP, AG100, and AG150. Previous studies provide evidence that
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the AP is an accurate and precise tool to estimate free-living SB as well as
transitions between sitting and standing (e.g., breaks per day) (32, 55, 64). Thus,
we feel confident that the AP estimates of SB metrics in our study can be
considered the ‘criterion measuare’.
In our study, AG150 recorded significantly more SB than both of the AP
and the AG100 and that the AP was not different than the AG100. This is
inconsistent with findings from Hart et al. who show that the AG100 recorded
significantly more sedentary time than the AP over a 15-hour period in adults
who were on average 30 years old and were of normal weight status (40).
However, the differences in SB using different cut-points for the AG are
consistent with findings reported by Kozey-Keadle et al. who found the AG100
cut-point was more accurate for sedentary time than the AG150 when compared
to the AP (56). Kozey-Keadle et al. note that the AG150 may misclassify
standing as sedentary behavior as one explanation for higher SB estimates using
this cut-point. In this study, breaks per day from both AG cutpoints were highly
overestimated compared to the AP, which is consistent with findings by Lyden et
al (64). Therefore, our findings for SB metrics are consistent with those found in
non-OA populations. These differences have important implications for
comparability among studies. The estimates of SB and breaks per day may not
be comparable and depending on the monitor used may provide a different
characterization of SB in the population being studied. Therefore, the
relationships that are identified or not between SB and health outcomes may
differ depending on the monitor used.
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It has also been determined that the AP can be used to determine
responders and non-responders to SB change interventions as it is sufficiently
sensitive to detect reductions in SB (56). In the larger study from which our
current data come from, there are also monitor data at the 3 month measurement
period for these participants. We examined the number of participants who
increased their SB by 5% from baseline to the 3-month time period. Five percent
was arbitrarily chosen, however, short-term SB interventions have reported
changes of 3-5% (30, 56). We were interested in increases in SB as we
hypothesized those with OA undergoing conservative, non-surgical treatments
would naturally increase SB over the course of the 9-month study as OA is
known to be a progressive disease (74). According to the AP, 15 participants in
our current study increased their SB by 5% from baseline to 3-months, but only 9
and 7 participants increased SB according to the AG100 and AG150,
respectively. The AP recorded an average change in SB from baseline to 3months of 6% where as the AG100 and AG150 recorded an average change of
0%. Since the AP has been shown to be an accurate and precise measure of
free-living SB, we consider this device to yield close to the ‘truth’ for changes in
SB. If only the AG was used, we would misclassify the change in SB for 6-8
participants depending on the cut-point used from baseline to 3-months. This has
major implications for the monitor used for intervention studies targeting changes
in SB. The AG is not sensitive enough to detect these changes, therefore, results
may indicate an intervention did not work when in fact it was successful in
changing SB. Our results are similar to those of Kozey-Keadle et al. and suggest
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that the AG may not be appropriate for studies designed to target changes in SB
or relate SB to health outcomes.
Another major finding is that there were significant differences between
the AP and the AG150 when data were presented as % of time spent in light and
MVPA, and steps per day. The differences were similar for the AP and AG100
with the exception of % of time spent in light activity where there were no
differences. Differences between the AP and AG for activity variables may be
even larger if using a wrist-worn AG as the wrist location records more activity
than the hip location (47). There were no differences between the AP and either
AG cutpoint when data were presented as guideline minutes or number of
guideline bouts. These data suggest that if comparing PA data across studies, it
may be important to compare time spent in MVPA in 10 minute bouts and
number of guideline bouts.
The last major finding was that there were no significant relationships
between accelerometer measured PA and SB at baseline with patient-reported
pain and function for the AP, AG100 and AG150. It is possible no relationships
were found because the instrument for pain and function was a self-report, and
there may have been misclassification and/or differential errors in report of pain
and function that would attenuate these relationships. Another reason for not
finding any relationships could be due to inherent limitations in the WOMAC. The
WOMAC was specifically developed to capture information about pain, function
and stiffness in individuals with OA. However, Alviar et al. suggest that patientreported outcome measures such as the WOMAC do not fully address relevant
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areas of activity in this population (4). For example, the WOMAC does not
address areas such as driving, community life, and assisting others. In addition,
another study demonstrated that the WOMAC did not address at least 50% of
patients’ issues (81). Therefore, the relationship between PA/SB variables and
patient-reported pain and function may exist, but the WOMAC may not be the
best tool to identify these relationships.
Data from the Osteoarthritis Initiative (OAI) support the idea that the way
in which physical function (objective versus subjective) may affect the
relationships that are found with PA/SB. In the OAI, participants spent about 67%
of their monitored wear time sedentary according to a SB measure from the AG
accelerometer (89). Based on the data from the AG100, our participants spent a
similar amount of time sedentary (66%). However, unlike our findings, there was
a relationship between SB and physical function in the OAI study. In the OAI,
physical function was measured using the 20-meter walk and chair stand testing,
which are ‘objective’ rather than subjective patient-reported measures of function.
This difference in how pain and function was measured could contribute to the
different results. It is possible that the accelerometer-measured PA/SB metrics
are providing different aspects of function compared to patient reports. Further
investigation into the relationship between patient reported outcomes and PA/SB
metrics is warranted as patient feeling and perception about disease symptoms
may be more important than the manifestation of symptoms themselves. In
addition, if SB is related to pain and function, this may be a more suitable
behavior to change than PA in a population with OA.
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The strength of the current study is the use of both the AP and AG to
measure SB and PA. This allows us to explore an accelerometer measurement
issue in a clinical population. In this current study, we used the AP as a criterion
measure for SB and for detecting changes in SB from baseline to 3-months. To
our knowledge, few published studies exist that use the AP in patients with
OA (63, 93). In one of the published studies with the AP, SB is not presented (93)
and in the other it is presented as hours spent lying or hours spent
sitting/standing (63) and does not account for wear time. It is unclear how the
authors separated lying and sitting time from the AP as it cannot distinguish
between these two SBs. A limitation to the current study is that while the AP
represents a criterion measure of SB, we do not have a criterion measure for the
activity variables. Another limitation is we could only use data from individuals
who had simultaneous AP and AG data. Therefore, our sample size is limited to
33 of our original 50 patients and is not ethnically diverse (100% Caucasian).
In conclusion, based on the results of this study, caution should be used in
comparing SB levels of patients with OA across studies using different
accelerometers such as the AP and AG. The similar estimates of guideline
minutes and guideline bouts suggest that if activity is presented using these
variables, cross study comparisons may be achievable. In addition, we show that
when possible, researchers should use the AP for studies that are specifically
designed to measure and/or change SB in patients with OA. In the future, the
relationship between other patient-reported outcomes and PA/SB metrics should
be examined.
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AP
% Sedentary
Breaks Per Day
Guideline Mins
Guideline Bouts
Steps Per Day

AG100

AG150
#

64.8±0.94
46.0±1.15
5.8±1.01
0.25±0.04
6699±217

66.3±0.67
15.7±0.33*
7.23±1.14
0.35±0.06
6059±222*#

71.1±0.64*
15.6±0.34*
6.7±1.12
0.32±0.05
5820±207*

Table 3. SB and PA measures from the AP, AG100, and AG150 at baseline
(N=33)
Data presented as mean ± SE
Notes: % Sedentary is expressed as a percent of wear time; AG100 refers to
results when using ActiGraph count cut-point 100 for SB, AG150 refers to results
when using ActiGraph count cut-point 150 for SB
Data includes 33 participants with valid data for all measures at baseline
*Indicates the variable was significantly different than the AP measure
#
Indicates the variable was significantly different than the AG150 measure

83

#

*

*

*#

Figure 15. Percent of time spent in difference intensities from the AP,
AG100, and AG150 at baseline
Data presented as mean ± SE
Notes: AG100 refers to results when using ActiGraph count cut-point 100 for SB,
AG150 refers to results when using ActiGraph count cut-point 150 for SB
Data includes 33 participants with valid data for all measures at baseline
* Indicates significantly different than the AP
#
Indicates significantly different than the AG150
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*

Figure 16. Relationship between percent of time spent in each activity
intensity (SB, Light, and MVPA) and the WOMAC for the AP (first column),
AG100 (second column) and AG150 (third column)
Notes: AG100 refers to results when using ActiGraph count cut-point 100 for SB,
AG150 refers to results when using ActiGraph count cut-point 150 for SB
Data includes 33 participants with valid data for all measures at baseline
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CHAPTER VI
OVERALL SUMMARY AND CONCLUSIONS
The overall goal of this dissertation was to study different aspects of PA
and SB measurement using wearable sensors to address a significant
knowledge gap about important measurement challenges confronting this field.
In study one, we evaluated the variability of SB and determined how many days
of SB measurement were needed to represent habitual SB. To do this, we
combined two existing data sets from the Physical Activity and Health
Laboratory. The combined data set included 62 adults and 34 adolescents who
wore an AP accelerometer for a seven-day period. The AP collection and data
processing methods were identical in the two studies. The seven days of AP data
were used to determine if there were day-to-day differences in SB and the
number of days that were needed to reliably estimate the seven-day SB
estimate.
In study two, we recognized the need to determine the feasibility of
assessing PA and SB with wearable sensors in a clinical population and
extended this feasibility to a longitudinal investigation to determine changes in
PA and SB over time in patients with progressive knee OA. The use of the AP to
measure these behaviors was central to our aims based on its accuracy,
precision, and ability to measure time spent in different postures
(sitting/lying,standing/stepping) as well as time spent in different intensities
(sedentary, light and MVPA) (32, 84). In study two, we collected data to quantify
changes in objectively measured PA and SB using an AP and AG during the

86

natural progression of OA at baseline (initial clinic visit to treat OA), three, six and
nine months, and to correlate these PA/SB metrics with patient-reported changes
in pain and function. Only the changes in AP measured SB/PA were presented
based on prior findings from our lab that suggest the AP is sensitive in detecting
changes in SB and the AG is not (55).
The use of accelerometers in patients with OA has increased over time
and this is a positive advancement in the field. However, our third study
addressed the current concern as to whether or not we can compare PA/SB
outcomes from studies that use different accelerometers worn at different
locations on the body. In study three, we used baseline measures from the
longitudinal study in OA (study two) patients to determine if the AG and AP
provide comparable estimates of different metrics of PA and SB in a sample of
patients with OA and to compare the relationships between patient-reported pain
and function and PA/SB measures from the AP and AG accelerometers.
Collectively, study one and three provided novel data to answer important
measurement questions regarding objectively measured PA and SB in both a
healthy population (study one) and a clinical population (study three). Study two
provided evidence that this is a feasible approach to longitudinally quantify
natural changes in PA/SB as OA progresses. A summary of the main findings
from each study is described below.
Study One
A major finding from study one was that there were small, significant dayto-day differences in SB in adults who ranged from 18 to 70 years old, but this
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observation was not observed in adolescents aged 12 to 17 years olds. Our
findings indicate that a minimum of two and three days is necessary to reliably
estimate SB in adults and adolescents, respectively.
Study Two
In study two, evidence is presented that the percent of time spent
sedentary and the number of breaks from SB is stable during the natural
progression of knee OA over three, six, and nine-months. However, there were
significant declines in all activity variables with the exception of percent of time
spent standing. The relationships found between all PA/SB metrics and
pain/physical function at all time-points were weak or non-existent.
Study Three
Data from study three indicated that there were differences in estimates of
SB metrics (% of time spent sedentary and breaks per day) among the AP,
AG100, and AG150. In addition there were significant differences between the
AP and the AG150 when data were presented as % of time spent in light and
MVPA, and steps per day. However, no differences were found for guideline
minutes and guideline bouts between the AP and AG. According to the AP, 15
participants in our current study increased SB by 5% from baseline to three
months, but only nine and seven participants increased SB according to the
AG100 and AG150, respectively. The AP recorded an average change in SB
from baseline to three months of 6% whereas the AG100 and AG150 recorded
an average change of 0%. The last major finding was that there were no
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significant relationships between accelerometer measured PA and SB at
baseline with patient-reported pain and function for the AP, AG100 and AG150.
Strengths
All three dissertation studies utilized the AP to measure SB and PA. In
study one, the AP was used to determine the number of days necessary to
reliably estimate habitual SB. In the second and third studies, the AP was used to
evaluate PA and SB metrics in participants with OA. The use of the AP as the
objective tool to estimate SB is a strength in all three studies, as it is an accurate
and precise measure of SB and this behavior is important to evaluate in both
healthy and clinical populations. The use of the AP was particularly important for
study two as it has been shown to be sensitive enough to detect changes in
SB (55), which was essential to the aims of the study. Collecting data
longitudinally in patients with OA was a strength of our study design as it allowed
for the characteristics of natural changes in PA and SB to be objectively
quantified in OA patients undergoing conservative, non-surgical treatments. We
had participants with OA wear both the AP and AG at baseline; therefore, we
were also able to answer a specific measurement question in this sample that
addressed concerns regarding whether outcome measures from these devices
are comparable.
Limitations
A limitation that extends to all three studies is that we were constrained by
our wearable monitor inclusion criteria. In study one, we only included
participants who had seven consecutive days of monitor wear. In study two, only
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participants who had valid wear data at all four time points were included in
analyses. Study three only included participants who had valid wear for all both
the AP and AG at baseline. Another limitation is that our samples across all three
studies were limited in diversity. In study one 75% of the sample and in study two
and three 100% of the sample with OA were Caucasian. Future studies will
benefit from including a more diverse population. Lastly, a limitation to the third
study was that while the AP represents a criterion measure of SB, we did not
have a criterion measure for the activity variables.
Significance and Future Directions
Study one from this dissertation provided critical evidence in
understanding how many days are necessary to reliably estimate habitual SB in
both adults and adolescents using an accurate and precise measure of SB. The
results of this study added to the paucity of data in the activity and sedentary
behavior measurement field and builds upon the limitations of the few studies
that have been conducted in this area by: 1) Focusing on a more diverse
participant sample (e.g., broad ages, BMI, and activity level), 2) Utilizing an
accurate and precise measure of SB that is increasingly being used in studies to
measure SB, and 3) Accounting for wear time presenting metrics as percent of
wear time. The findings from this study suggest that two and three days are
necessary to provide reasonable estimates of SB from seven-days of monitor
wear in adults and adolescents, respectively. Requiring only two or three days of
data to estimate habitual SB reduces participant burden and allows researchers
to include more participants in studies requiring SB measurement. This is also
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significant because it provides evidence of an advantage to using an accurate
and precise measure of SB rather than a method such as self-report. Self-report
tools for measuring SB have been shown to have high variability and limited
agreement with criterion measures and are not recommended for use in
longitudinal or intervention studies that need to assess change in SB
overtime (43). Therefore, only needing two to three days of data from an
accurate and precise tool for measuring SB makes this measurement method
appealing for clinical and academic researchers.
Data from this study also suggested that SB is significantly different on
weekend days compared to weekdays in overweight/obese individuals, but not in
normal weight individuals. This is significant as it suggests that including a
weekend day may be important if the particular study sample includes
overweight/obese individuals. We also found that in our adolescent sample, the
variability throughout the week was higher in those who were in school compared
to those not in school. Although there were no significant day-to-day differences
even in those individuals not in school, we only had 11 participants who were not
in school during our study period. Therefore, this warrants further investigation. In
addition, future studies should examine the influence of other participant
characteristics such as employment status, number of hours worked, and race on
SB variability.
Data from study two added new information to the limited number of
studies on objective measures of PA and SB in patients with OA. While more
research groups are recognizing the importance of establishing objective
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measures of these behaviors in clinical populations, the longitudinal study design
in our current study improved and standardized procedures for these objective
measures of SB and PA and determined how these behaviors change as the
disease naturally progresses. We found that SB remains stable over a 9-month
time period in adults with OA. However, there are declines in PA over this same
time period. Data suggest that maintaining a physically active lifestyle is
important to manage symptoms of OA (13). Therefore, our study results suggest
that PA should be a specific target of interventions in individuals who are being
non-surgically treated for OA. These data can also be used to aid in the
development of appropriate PA and SB guidelines in this population as our
results provide information on the current activity level exposure in individuals
with OA.
Future studies in this area should focus on a larger, more diverse sample
size that includes individuals receiving non-surgical and surgical interventions to
compare the patterns of behavior among different stages of this progressive
disease. This will also add to our understanding of whether PA/SB metrics from
these devices can improve our understanding of their diagnostic value for
evaluating effectiveness of different treatment modalities in patients with OA or
other diseases and conditions where quantification of movement is relevant for
clinical purposes. Lastly, future studies should determine how PA/SB from the AP
are related to momentary symptoms of OA. Our patient reported outcomes were
assessed at one time-point at the beginning of the week. Future studies should
examine how within day patient reported pain/function is related to PA/SB
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metrics from the AP. Momentary fatigue has been shown to be associated with
decreased PA in patients with OA (75).
Study three results have significant implications regarding objectively
measured PA and SB in adults with OA. First, our data suggest we have to be
cautious in our comparisons of activity levels across studies that use different
monitors especially in terms of SB measurement. Second, our data also suggest
that comparing data across studies in PA guideline bout minutes and number of
guideline bouts are possible even if different monitors are used to assess PA.
This is significant because these two measures are important from a public
health perspective to quantify achievement of activity dose associated with
health. Third, our data are in agreement with other studies that found the AG is
not an appropriate tool to measures changes in SB. This is vital information for
studies that use the AG to estimate pre and post SB for an intervention designed
to change this behavior. If the AG is the tool of choice, it is possible that the
intervention may have decreased SB, but the AG data would not be sensitive
enough to detect the impact of the intervention. However, while the AP is
considered as a criterion measure of SB, future studies should include a criterion
measure for PA to determine which monitor was more accurate in capturing
activities levels. Future studies should determine if SB/PA metrics from different
devices can discriminate between those with OA and healthy controls. Our
current study sample was being conservatively treated (e.g. physical therapy)
rather than being surgically treated for OA. Future studies should determine if
these PA/SB metrics from these devices can be used pre/post surgical
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intervention to determine success of treatment (e.g., increases in PA/decreases
in SB) and/or discriminate among different stages of the disease.
In conclusion, the work conducted for this dissertation advances the field
of PA and SB measurement using wearable devices. The results from the first
study provided evidence that when using an accurate and precise measurement
tool to measure SB, only two to three days rather than the commonly used
seven-day monitoring period are needed to reliably estimate SB. This finding will
help future studies by reducing participant burden allowing researchers to collect
sufficient data that can ultimately lead to the creation of guideline
recommendations for SB. Collectively, data from the second and third study set a
standard for how PA and SB metrics should be measured in clinical populations.
The characterization of these behaviors should provide more detail than just time
spent in different intensities and should include metrics such as guideline
minutes and breaks from sedentary time, both of which have been linked to
health outcomes in the literature (44, 45). While this dissertation focused on a
population with OA, over time, there will be an increased interest in measuring
these behaviors in other clinical populations. The results from the studies in our
OA patients pave the way for these future studies. With the increased utilization
of these devices, based on results from study two, it will be important to
standardize reporting from these devices so that data in the literature are
comparable. Researchers may also benefit from a standardized monitoring
protocol that can be used in such studies. The results from study three
demonstrate that it is feasible to measure PA/SB metrics over time to determine
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specific targets for future interventions. While we did not find any evidence of a
relationship between patient-reported pain and function and PA/SB metrics, it will
be important for future studies in different clinical populations to determine if
these metrics can provide an objective functional outcome measure to determine
effectiveness of different treatments. PA/SB metrics from wearable devices may
ultimately become a best practices outcome measure in future comparative
effectiveness trials.
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APPENDIX A
AMENDMENTS TO ORIGINAL DISSERTATION PROPOSAL
The original third study for this dissertation was entitled “Effects of
angioplasty intervention on physical activity and sedentary behavior in patients
with peripheral artery disease”. This third project would have been an application
of wearable devices to measure in an additional clinical population.
The primary goal of the proposed project was to evaluate objectively measured
free-living PA and SB in patients with peripheral artery disease (PAD) before and
after angioplasty with potential insertion of an arterial stent to increase lower
extremity blood flow. This would help to determine how effectively this commonly
used PAD intervention impacts free-living PA and SB. Ten patients with
claudication were going to be recruited from the Vascular Surgery Clinic at the
UMass Memorial Medical Center. Participants were going to wear an AP
accelerometer to estimate PA and SB levels for 7-days at baseline, 14-days after
angioplasty, and 7-days one-month post-angioplasty. Patients were going to also
report on their quality of life and perform a six-minute walk test. This would allow
for examining the relationship between self-reported quality of life and free-living
activity and how that compares to the relationship between self-reported quality
of life and a laboratory test of functional capacity (six minute walk test). However,
despite the help we had recruiting patients via the UMass Memorial Medical
Center, we encountered recruitment challenges early in this project.
While we were able to recruit one participant very quickly and obtain the
patient’s data seamlessly; this was not the case for the next participants. There
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was a gap of 3.5 months between the first and second participant recruitment.
Several factors contributed to the slow initial enrollment. The main contributor
was an influx of clinic patients presenting with tissue loss in addition to their
claudication. The tissue loss deemed them ineligible to participate in our study.
There were a few other interested participants who were consented but also
deemed ineligible based on findings from their angiogram.
Due to the fact each participant would be enrolled in the study for a total of
28 days, it was determined that it would not be feasible to complete this
dissertation in a timely manner. This third study was, therefore, supplemented by
answering additional research questions from the study longitudinal study that
was conducted in patients with OA. Each committee member approved this
decision in a meeting on May 2, 2016.
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APPENDIX B
SUPPLEMENTAL FIGURES FOR STUDY TWO

Relationship between percent of time spent sedentary and the WOMAC score at
each timepoint

Data includes 36 participants with valid data for all four time-points

Relationship between breaks per day and the WOMAC score at each timepoint

Data includes 36 participants with valid data for all four time-points
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Relationship between percent of time spent in light activity and the WOMAC score
at each timepoint

Data includes 36 participants with valid data for all four time-points

Relationship between percent of time spent in MVPA and the WOMAC score at
each timepoint

Data includes 36 participants with valid data for all four time-points
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Relationship between percent of time spent stepping and the WOMAC score at
each timepoint

Data includes 36 participants with valid data for all four time-points

Relationship between steps per day and the WOMAC score at each timepoint

Data includes 36 participants with valid data for all four time-points
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Relationship between time spent in guideline minutes and the WOMAC score at
each timepoint

Data includes 36 participants with valid data for all four time-points

Relationship between total number of guideline bouts and the WOMAC score at
each timepoint

Data includes 36 participants with valid data for all four time-points
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APPENDIX C
SUPPLEMENTAL FIGURES FOR STUDY THREE

Relationship between total steps per day and the WOMAC for the AP (first
column), AG100 (second column) and AG150 (third column)
Notes: AG100 refers to results when using ActiGraph count cut-point 100 for SB,
AG150 refers to results when using ActiGraph count cut-point 150 for SB
Data includes 33 participants with valid data for all measures at baseline
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Relationship between total time in guideline minutes and the WOMAC for
the AP (first column), AG100 (second column) and AG150 (third column)
Notes: AG100 refers to results when using ActiGraph count cut-point 100 for SB,
AG150 refers to results when using ActiGraph count cut-point 150 for SB
Data includes 33 participants with valid data for all measures at baseline
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Relationship between total number of guideline bouts and the WOMAC for
the AP (first column), AG100 (second column) and AG150 (third column)
Notes: AG100 refers to results when using ActiGraph count cut-point 100 for SB,
AG150 refers to results when using ActiGraph count cut-point 150 for SB
Data includes 33 participants with valid data for all measures at baseline
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Relationship between breaks per day from sedentary time and the WOMAC
for the AP (first column), AG100 (second column) and AG150 (third column)
Notes: AG100 refers to results when using ActiGraph count cut-point 100 for SB,
AG150 refers to results when using ActiGraph count cut-point 150 for SB
Data includes 33 participants with valid data for all measures at baseline
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